Archive for October, 2020

By Jolene Marriah-Maharaj Oct 28, 2020

Share this article:

Durban - A Durban mother, who is the first black woman to graduate with a PhD in leisure and recreation from the University of KwaZulu Natal, is hoping to change the lives of children living with disabilities.

Khumbuzile Khumalo, fondly known as KK, recently graduated from the College of Health Sciences.

Her PhD is entitled The development of a policy framework for physical activity and sport for children with disabilities in schools in disadvantaged communities in KwaZulu-Natal.

Her study resulted in a policy framework for physical activity and sport for children with disabilities (CWD) in schools in disadvantaged communities in KZN.

The provision of sport facilities and equipment suitable for CWDs requires a collaborative effort between the Department of Sport and Recreation and the community stakeholders to address long-standing barriers, said Khumalo.

In developing the policy framework, Khumalo ensured that CWDs and their families contributed significantly, thereby ensuring that their voices were heard.

The new policy framework that aims to enhance the physical activity of CWDs will be presented to the Department of Sport and Recreation with the intention of it being adopted and implemented in KwaZulu-Natal, especially in schools based in poorly resourced communities.

I have a passion to work with people with disabilities. Currently, I am a member of the interim UKZN Division of Sport Union Executive Sport Organising Committee.

Last year, we launched the UKZN Disability Sports and Leisure Association. This association included all students with disabilities on all UKZN campuses.

Khumalo, who works at UKZN, was born in a township called Steadville in Ladysmith.

She has one son who graduated with a PhD in genetics from Stellenbosch University in 2017 and lives and works in Norway.

In her free time, Khumalo enjoys reading, socialising, travelling, and going to church.

She thanked all those who supported her during her studies, including family members, Bongiwe Gumede, colleagues, and Dr SB Radebe for their encouragement and inspiring words of support that enabled her to reach her final destination.

She described her supervisors, Professor Rowena Naidoo and Professor Verusia Chetty, as her beacons of hope.

Both my supervisors believed in my passion for CWDS, my ability to complete my PhD and supported me all the way.

Naidoo and Chetty said: We believe that team work is key, and as supervisors we believe that supporting a candidate and making them believe in themselves is key to succeeding.

We are excited to share KKs policy framework with the related governing structures.

IOL

See original here:
UKZN boast its first black female graduate with a PhD in leisure and recreation - IOL

This article was developed with help from Global Citizen fellows Aaron Rakhetsi, Ntombizodwa Lephuma, and Buhle Dlulane.

Why Global Citizens Should Care

Young people dont often view the agricultural sector as a viable and economically sustainable career path an oversight that could threaten the future of food production.

As a result of the massive reduction of young people entering the profession, agriculture as a whole has been on the decline at a time when the world faces enormous pressure to produce more food in a less hospitable climate. But a simple reconceptualization of the field an effort being undertaken by a crop of new farmers could change how young people view it.

Agriculture doesnt have to mean subsistence farming, even for family farms. With increased access to education, young people can be a force for innovation on family farms, increasing incomes and well-being for not only farmersbut also for their local communities.

By tapping into their skills, energy, creativity and willingness to take risks, African youth in particular could play a critical role in revitalising rural communities and enhancing agricultural productivity.

Global Citizen recently spoke with Gugulethu Mahlangu, a 27-year-old farmer in the town of Boksburg near Johannesburg, South Africa. In 2020, she launched her agricultural business, Harvest House, through which she farms spinach, rapeseed, green beans and hubbard squash.

Mahlangu answered questions about her career, views of agriculture, and what it takes to start a home garden.

Global CItizen: What inspired you to go into agriculture? Has it always been something that you thought you would end up doing?

Gugulethu Mahlangu:I studied it in my first year of university but left it to study human physiology, genetics, and psychology. I left university and I was not happy with my career choices. I realized that agriculture has always been a sign throughout my journey. My late grandmother was a farmer, and I enjoy nature, being independent, and working for myself. Agriculture was the light at the end.

GC: What type of farm do you own? Why did you choose this over the other types of farming?

Im already in my fifth year of being on a plant-based diet. Nutrition is very important to me, so choosing to grow vegetables was a natural choice for me.

Related Stories May 1, 2019 9 Reasons Why Plant-Based Meat Is the Food of the Future

GC: How would you describe your journey thus far as a young Black woman in farming?

A tough but rewarding experience. They say do what you love and youll never work a day in your life. Im proud to have been on this road as a young Black female because Ive made my family proud and have served as an inspiration for younger Black girls to join the agriculture sector. That has truly been rewarding for me, to see more young Black girls take up the space.

GC: What are the challenges you have faced since you started farming?

Funding has been a real challenge for me. Agriculture is a business and it's costly. I have currently not received any funding and Im working tirelessly to grow my business with the means I have.

GC: What are your views on sustainable farming and do you practice it at your farm?

Sustainable agriculture is important for every farmer to practice. We use recycling methods such as chicken manure and crop waste to make organic fertilizer which naturally enriches our soil. We also do crop rotation which helps maintain nutrients in the soil. I believe every farmer needs to farm with the consciousness of protecting the ecology of the land and promote foods conducive for public health.

GC: What would you say to other young people out there who want to go into farming?

I would say, go for it. Just make sure you are passionate about it because it is a lot of consistent hard work and it needs you to be focused. If its in you Id encourage them to take up space because their dreams are valid and the sector is big enough to enter, grow and be successful in.

GC: What type of farming would be best for someone without a background in agriculture?

I would advise to start a hobbyist farm. Start small. If youve always wanted to venture into agriculture as a career, its important that you learn. Whether you start with a few chickens or a small backyard garden, youll be able to distinguish how your dream will be achieved on a larger scale. You cannot do agriculture without some sort of experience so I would suggest that. Youll learn as you go and decrease your rate of failure with more time and cultivate a love for it. Soon youll want to expand and buy more chickens or seeds.

GC: Tips on how to start your own garden at home?

Start small;this will lower the risks of mistakes that might occur and costs. Talk to other farmers;this will allow you to not feel alone and get advice on things that you might have missed. Work at trying to get profit. Maximize your space by trying to get something out of it. This will help you learn agri economics, and it wouldnt hurt in case you might want to go bigger. Embrace sustainable practices. For example, get yourself a chicken waterer out of a plastic bucket instead of buying it. Read and research. Your garden will need you to have knowledge about at least the basics and it can save you a lot of time to just know some things, education is everything.

Related Stories June 5, 2019 This Community Garden Is Fighting Food Insecurity in Rural Benin

GC: Which crops are easier to maintain for a small home garden and why?

Tomatoesyou can harvest throughout the season. Basil, like most herbs you can grow it indoors, too. Spinach easy to grow and the mother plant gives you more leaves when cut. Bell peppers because theyare low maintenance crops that love the sun and heat to grow. Lettuce, old resistant crops that can grow and be planted directly in the soil.

GC: What methods would you advise someone to use to handle or control pests and weeds?

Mulching, because it suppresses weeds. Zero tilling because disturbed soil encourages weed growth so do less of it. Use a scarecrow for birds and choose resistant varieties to grow. Crop rotation which will help with reducing the pest population.

Visit link:
This Young Farmer Has Advice for Anyone Who Wants to Grow Food - Global Citizen

Elections can be bad for your health.

Actually, any large-scale stressful event causes a national increase in the incidence of heart attacks and strokes, according to researchers who tracked hospitalizations for heart disease before and after the 2016 presidential election. They found that hospitalizations for cardiovascular events were 61% higher than the same two days of the preceding week. The results were the same regardless of corrections for age, race or gender.

The precise cause is unknown.

Obviously, the theory is stress spread broadly enough that it impacts nationwide numbers when examining millions of people is the reason. Common national events simply encompass the national consciousness of the entire population and its not simply elections that capture everyones attention. Cardiovascular disease event risk increases similarly after any traumatic public event, such as earthquakes or the terrorist attacks on the World Trade Center in 2001.

Anxiety is simply a psychological stressor associated with cardiovascular events and nearly 70% of respondents to a recent American Psychological Association survey said elections were a significant source of stress. This study was also the same regardless when correcting for age, race, gender or even political affiliation. Its a bi-partisan concern. The coronavirus pandemic that has filled headlines certainly only adds to the stress this time of year. We can call it a bit of headline stress as well. But there are some ways to cope.

First, prepare ahead for uncertainty. Stressful events leave a lot of questions. The unknown can be more stressful than reality. Mentally prepare in advance for things like election delays, favorite candidates winning or losing and simply expect uncertainty. If watching the news is stressful, do something less stressful. Try not to obsess over the uncertainty of evolving events. Plan ahead to be active doing less stressful activities.

Secondly, increase stress reducing efforts. This means eating extra healthy. Get sufficient sleep and exercise. Maintain social interactions and support.

Also, plan alternate activities around stressful events. This may mean unplugging from the news and reading a book, listening to music or planning an activity with family. Staying abreast of news is important. But fill time with less stressful activity as well.

Lastly, be hopeful. Regardless of whether or not the stressful event is an election or some other stressor, most Americans when surveyed report that they remain hopeful despite their stressors. This is encouraging. Having something to look forward to is important. Seeing the horizon helps get a person through many obstacles when they look positively toward the future rather than focusing on present distress.

Whether its election distress, headline distress or social media distress, the idea is to take a break from these stressors and engage in alternative pursuits during the period of stress. Limit consumption of news or social media if necessary. Rather than being consumed by immediate events, be hopeful about future possibilities.

Even though elections are over in November, holiday season is close behind. Stressors dont go away after elections, they simply change and the holiday season can be stressful for many. Treating yourself to relaxing activity is vital to prevent stressors from manifesting themselves into more serious cardiovascular events that are also present during holidays. It makes managing stress during election season and heavy news cycles even more important when Thanksgiving and Christmas soon follows the same year.

Phillip Stephens, DHSc, PA-C is affiliated with Carolina Acute Care & Wellness Center, P.A.

Read more:
Help your health by taking breaks from stress - The Robesonian

Q3 2020 Energy Recovery Inc Earnings Call San Leandro Oct 30, 2020 (Thomson StreetEvents) -- Edited Transcript of Energy Recovery Inc earnings conference call or presentation Thursday, October 29, 2020 at 9:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Bob Mao * James Siccardi Energy Recovery, Inc. - VP of IR * Joshua Ballard Energy Recovery, Inc. - CFO ================================================================================ Conference Call Participants ================================================================================ * Pavel Molchanov * Ryan James Pfingst B. Riley Securities, Inc., Research Division - Associate ================================================================================ Presentation -------------------------------------------------------------------------------- Operator [1] -------------------------------------------------------------------------------- Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the Energy Recovery Third Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions) Please note this conference is being recorded. I will now turn the conference over to your host, James Siccardi, Vice President of Investor Relations for Energy Recovery. Thank you, you may begin. -------------------------------------------------------------------------------- James Siccardi, Energy Recovery, Inc. - VP of IR [2] -------------------------------------------------------------------------------- Good afternoon everyone, and welcome to Energy Recovery's 2020 third quarter earnings conference call. My name is Jim Siccardi, Vice President of Investor Relations at Energy Recovery. I'm here today with our Chairman, President and Chief Executive Officer, Bob Mao; and our Chief Financial Officer, Joshua Ballard. During today's call, we may make projections and other forward-looking statements under The Safe Harbor provisions contained in the Private Securities Litigation Reform Act of 1995 regarding future events or the future financial performance of the Company. These statements may discuss our business, economic and market outlook, the Company's ability to commercialize VorTeq, growth expectations, new products and their performance, cost, structure and business strategy. Forward-looking statements are based on information currently available to us and on management's beliefs, assumptions, estimates or projections. Forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors. We refer you to documents the Company files from time to time with the SEC, specifically the Company's Form 10-K and Form 10-Q. These documents identify important factors that could cause actual results to differ materially from those contained in our projections or forward-looking statements. All statements made during this call are made only as of today, October 29, 2020, and the Company expressly disclaims any intent or obligations to update any forward-looking statements made during this call to reflect subsequent events or circumstances, unless otherwise required by law. At this point, I would like to turn the call over to our Chairman, President and Chief Executive Officer, Bob Mao. Bob, the floor is yours. -------------------------------------------------------------------------------- Bob Mao, [3] -------------------------------------------------------------------------------- Thank you, Jim. And thank you everyone for joining us today. I want to start today's call as I did last quarter, with sincere hope that everyone listening and your families are safe and healthy. Once again, I am happy to report that the Energy Recovery team and our business remain healthy and strong. Energy Recovery is evolving well into a COVID inspired new normal, where we continue to steadily achieve growth those in our base business as well as in our new business initiatives. The disciplined finance financial and time bounded approach to our new initiatives as recorded in our last call is being strictly executed, which should translate to a greater bottom-line results and increase returns for our investors. Following the format of my previous earnings call report, I will provide you updates to our Water business and VorTeq development in our Oil & Gas business. In addition, in our last earnings call, we committed to provide more details on our intubation effort for the PX technology platform, which was started at the end of the first quarter of this year. Today, we are happy to report our one of the efforts ZLD, Zero Liquid Discharge, which has just graduated into commercialization with receipt of the first purchase order. Let's begin with our water business, which continues to be healthy and strong, riding on incredibly strong global desalination grows even amidst the COVID pandemic. This third quarter was ERII's biggest water revenue generating quarter, eclipsing last year higher quarter record by 26%. At this time, we feel competent increasing our previously projected 20% to 25% of water's revenue growth for fiscal year 2020, up to 25%. We also feel confident in increasing our 2021 growth outlook to 10% from the flat to 5% gross we communicated last quarter. Finally, adjusting desalination industry trends allows us to optimistically anticipate water revenue growth in 2022 similar to what we are achieving in 2020. The strong global seawater reverse osmosis desalination growth trend is anchored in equivalent need to provide access to clean water in many parts of the world. In addition to the basic need, three other trends are helping to grow in seawater reverse osmosis. First, the technological shifts, from inefficient thermal desalination plants for reverse osmosis is becoming the growing portion of our pipeline. Second, acceptance of private financing into desalination construction in places like Saudi Arabia, Dubai, Egypt and India is increasingly decoupling desalination projects to national fiscal budgets, which you may be susceptible to oil price increase and COVID-19. And finally, geopolitical shifts are creating an urgent strategically move for desalination in countries like Egypt, where the construction of Nile river dam in Ethiopia, to recognize Egypt's water independence. In addition to our fundamentally strong baseline seawater reverse osmosis outlook, our first incubation initiative Zero Liquid Discharge or ZLD is focused on our water business specifically with wastewater industry. In fact, we are excited to announce that we received our first commercial purchase order to our new water wastewater product from a customer in India just this last week, which is really encouraging. A global regulatory push is currently being led by China and India to implement more environmentally friendly practices in industrial wastewater treatment. Those countries are struggling less maintaining clean water sources and they are seeking to maximize the recovery of clean water and minimize the impact of wastewater disposal polluting theirs water wastes. ZLD allows for this by fully removing the harmful industrial waste from the water and reintroducing or recycling only clean water. The ZLD market is in its nascent stages. It is fragmented market and the multiple competing technologies, none of which has emerged as a dominant technology. Much like the desalination market, we believe our reverse osmosis is the upcoming solution. However, unlike desalination the pressures needed to achieve zero or minimum liquid discharge are nearly 2,000 psi or roughly double that our seawater desalination. To address this, we are using our PX technology platform to build our high pressure PX application, which we call the Ultra PX. We believe our technology has the potential to become the dominant solution in ZLD wastewater just like our legendary PX has dominated the seawater reverse osmosis market. Our preliminary ZLD market research identified existing wastewater applications of our Ultra PX. There is a potential total addressable market in China as high as $100 million, which would not include further annual growth as the market expense. We see a similar opportunity in India, where we recently received our first purchase order, and we believe that markets globally will move further toward those new and minimal discharged technology overtime as clean water becomes a more critical resource. Nowadays, it has achieved commercialization, ZLD will move out of incubation and into our water business unit. We're proud of our R&D and commercial teams and their ability to commercialize our new Ultra PX with the several months' initial incubation well below our three years project movement. ZLD should achieve and returns on investment far exceed 20% and we anticipate ultimately achieving margins at levels comparable to our base water business. Finally, we anticipate positive operating cash flow around the asset with our first purchase orders in hand. We're truly confident in the potential of our water business, as we look forward. Our business, our baseline seawater desalination business continues to enjoy a superior upswing. There's no end in sight over the next few years and we're excited about the potential of our new wastewater business efforts. We look forward to update you on both in the future. Next, we turn to our Oil & Gas business and VorTeq where I continue to view the progress we made with great pride. We have developed our production model 1.0, which was utilized during our previously reported few simulation frac with Liberty oil fuel services. However, the three hurdles we outline must to be clear before we commercialize. One, successfully complete 2 to 3 live fracs. Two, validate our customer value proposition. And three, maximize the amount of sand that can be pushed through the cartridges before repair or replacement. As I said beginning of live frac and by extension our value proposition, we are aggressively seeking to get out in live frac before year end as live frac verification is critical to establishing the VorTeq value proposition for our customers and to verify our VorTeq cartridge service spec. In addition to our ongoing dialogue with Liberty, we have taken calls from and hosted indicators for additional oilfield service companies interested in the potential use of VorTeq. We are pleased with the response companies are giving us and the willingness which they have introduced VorTeq to their own customers. We remain confident in our ability to achieve the live well requirements as outlined last quarter and quantifying our value proposition. As soon as we have achieved our first live well, we will let you know. With regard to the final hurdle, we're making solid progress in cartridge life extension and manufacturing insurance. We believe we identified a solution to achieve our cartridge life or as a minimum, a solution that will give us a material step forward to this end goal and we will be testing the solution as we end the year. We're continuing to remind ourselves the new to commercialize VorTeq by midyear 2021 or I'll stopping this. Our committed timeline has not changed. Next, we report on incubation. I discussed earlier our ZLD initiative, the first incubation efforts to graduate to an exciting business unit. In addition to the ZLD market, there are a multitude of potential applications for our ultra-high pressure PX in a variety of industries within and outside of water. We see significant future potential for our ultra-high pressures PX technology and believe it could become a significant percentage of our revenue in the coming years. We're also making progress on the second PX incubation initiatives targeted at a very large growth of industry currently undergoing regulatory driven transformation. While this product has the potential of being transformative in much the same manner, the PX transformed the desalination industry, we are at the technology feasibility stage and so we'll forego detail discussion at this time. We expect to report on the progress of incubation efforts when we speak to you again in March, at which time, we will have either prove out technically feasibility or seek investment. Finally, we mentioned last quarter that we are working on a project that will expand the aperture of our PX technology platform, thereby creating new PX applications in new industries. This project is a zero mixing PX. Zero mixing simply means that there is no commingling of fluids as columns of liquid transfer their pressures within the PX. Such mixing dose occur in our current applications in desalination and in oil and gas, but mixing however slight can exclude the PX from the applied in many applications such as gas processing or chemical among others where our technology could potentially help reduce energy consumption and thereby cost new existing systems. We have already proven the technical feasibility of this extension of our technology and we are now working on longer life and reliability. As we begin to apply this technology to new applications, we will update you on our progress and the potential of these new markets. With that, let's turn to ESG. As you know, we released our inaugural ESG report in September. While our business has always been aligned with sustainability issues such as addressing global water scarcity and improve access to affordable and clean energy. Our ESG report reflects our commitment to become more sustainable and resilient business. The initial guide to build our ESG program will base on our business growth as well as inputs from our key stakeholders. The pursuit of more efficient, sustainable customers' solutions has been the core of our DNA, since our founding more than 20 years ago. We're proud of the impact that our technology has been making desalination more efficient and sustainable particularly as our growth comes from growing water scarcity. Our new ventures will continue to focus our energy efficiency and endowment. As we use own pressure exchange technology to drive new growth opportunities, we desire to do so while providing new efficient and sustainable solutions to industrial needs. This is an exciting time at Energy Recovery. Our water team is focused on maintaining the momentum of our desalination business as well as expanding our reach with launch of the new ZLD product. Our Oil & Gas team is focused on finding finance and commercializing VorTeq. And finally, our incubation efforts are focused on achieving technical verification on one product that could prove transformative and another that could further expand the aperture of our PX phase platform. We're transitioning Energy Recovery into a growth company on the basis of our very versatile pressure exchanger. We are giving you insights to this transition by reporting our progress, our wins and our failures. We are investing our hard earned cash and you should know how and why we are investing it. We will continue to tell you what to expect, give you updates on our progress, and provide details on the outcomes. If we fail, you will know why. But when we succeed, you should not be surprised. In short, you will see every punch we land and every step we take, and we do not plan to take hand fist. With that, I hand other over to Joshua. -------------------------------------------------------------------------------- Joshua Ballard, Energy Recovery, Inc. - CFO [4] -------------------------------------------------------------------------------- Thank you, Bob. As you saw last quarter, each channel in the water business continues to experience different dynamics. Mega-projects remain dominant, growing 70% year-on-year in the quarter and an impressive 48% year-to-date. As expected both the OEM and aftermarket channels remain weak as compared to 2019, falling 22% and 40% respectively in the quarter from a year ago. Based on Bob's affirmation of at least 25% growth in our Water business this year, you should expect a very strong fourth quarter. I've mentioned in the past calls that it's hard to pinpoint quarterly trends in our business. In both 2018 and '19, we experienced the drop off in sales in the fourth quarter. However, this year, our fourth quarter sales should be comparable to that of the third quarter. As we looked at '21, and '22, we do expect to see our OEM and aftermarket channels recover; however, the extent of that recovery will largely depend on the global effects of COVID over this winter and next spring. While some industries will remain weak within these channels regardless, most notably travel and hospitality. At this time, we believe pent up demand and other industries may help return the OEM and aftermarket channels to more normalized levels, which is leaning toward increased confidence in projections for next year. I should also note that revenue from our new ZLD market is not yet included in these projections, as we build our pipeline and grow more comfortable, will provide more clarity. That being said, it's probably fair to assume that our initial revenue will be in the single digit millions the first couple of years, with considerably more growth in the future. Also note that these projects will be of a different nature than the larger Mega-project desalination plant driving our water growth today. A typical ZLD project will be in the range of $50,000 to $150,000 in revenue, with our potentially a much larger number of these projects than we've seen in desalination. For example, if we assume $100 billion market in China, as Bob outlined, this will imply roughly 100 projects, whereas in desalination it could be as low as 10. Our product gross margin decreased by 360 basis points as compared to Q3 2019 which showed a healthy 550 basis point increase from our low mark in the second quarter of this year and somewhat exceeded our expectations this quarter. Our margin strengthening over last quarter is largely due to our return to normal production levels at the end of Q2. While we did have a small effect from COVID due to delay in the commissioning of our new ceramics plant in Tracy, California, that effect was muted compared to prior quarters. We are pleased with how well our manufacturing team is operating within the restrictions of COVID and we continue to work under strict protocols to ensure the safety of our employees as well as the continuity of our business. In addition, our decreased OEM sales led to lower than expected sales of turbochargers and pumps, which proved accretive to margins as these products are less profitable than our PX sales in this channel. Last year, we mentioned some margin pressure owning the low ASPs as a result of bigger order sizes as we serve ever larger desalination process. We expect the trend to continue in Q4 and around the fiscal year with roughly 68% to 69% gross margin despite a reduced effect from COVID. As we look to 2021, the fundamentals of our gross margin will remain largely the same, excluding the potential of any temporary COVID-19 related effects. At this time, we don't expect to see a shift in our water business outside of this 68% to 70% range. Let's now turn to our operating expenditures where we have reported a decrease of 9% compared to Q3 2019. While our OpEx is somewhat lower than planned today due to COVID, the real story is an R&D where you will see a 23% decrease compared to Q3 last year and a similar decrease as compared to the first half of 2020. While our R&D expense may increase somewhat in Q4, we expected to remain roughly 15% to 20% lower than the first half of 2020. If there is a single thing at bottom I want you to hear, it is that of discipline, discipline in our R&D efforts as well as our operations and by extension, our expenses. For example, this year we terminated some projects altogether that were not achieved our commercial KPIs in expenses from these projects. And as we look at our OpEx going forward, while we expect OpEx to grow, you're focused on reducing our spend as a percentage of revenue over the next 2 to 3 years to a more normalized level as related to our peers in the market. Over the past decade, we have reported annual OpEx higher than 60% to 65% of revenue every year. It would have been in a similar range this year and after the second quarter termination of this Schlumberger contract and subsequent GAAP recognition of the remaining license and development revenue. We are targeting our OpEx to drop to a range of 35% to 40% of revenue by 2022, subsequently to reduce it to the low 30s, which will be more in line with our peers in the market. Sustaining of OpEx will be done in two ways. First, we will be capping our R&D as a percent of revenue in our baseline budget. Our R&D expenses averaged over 20% of revenue in the past few years due to our elevated spend on the VorTeq. In 2021, we'll be targeting a range closer to 15% to 20%, with the goal lowering it further in 2022 towards a 10% to 15% range. Keep in mind that this percentage will be decreasing despite the fact that we are guiding total revenues lower next year due to this year's increase in revenue from the termination of the Schlumberger contract. You can expect a clear reduction in R&D by the second half of next year, as we reduced spend on the VorTeq and wind down those R&D activities. In addition, based on R&D spend on our incubation projects is expected to remain in the single digit millions a far cry from the levels that we saw with the VorTeq. Second, we will continue to leverage our existing infrastructure, which will slow G&A growth in the coming years. We have invested significantly in the new systems past 18 months to better modernize our operations, to leverage our back office as we grow and we should see the fruits of this labor as we expect G&A spending growth to continue to lag that revenue. This year G&A spend is somewhat lower than plan due to COVID-19. Next year, we expect more normalized G&A spend and growth will generally occur from inflation and a reversion to the norm rather than increasing resources. I expect total G&A to grow more than 10% in 2021 and further decrease in growth on subsequent years as like R&D we aim to reduce G&A as a percent of revenue to the mid to high teens over the medium to long term. Sales and marketing spend is expected to stay roughly where it is today, around 10% to 12% of revenue. Lastly, as we concern OpEx, please keep in mind that our current levels spend is soon success with the VorTeq. If the VorTeq does not commercialize in 2021, our overall OpEx spend would decline considerably as we reduce activities in our Oil & Gas business unit and cease R&D. If modeling you keep similar levels of OpEx, you should then assume revenue from the commercialization of VorTeq. If we commercialized the VorTeq, we expect up to a 40% to 50% reduction in Oil & Gas OpEx spend overall, with about half of that reduction due to shifting spend in the cost of goods sold once we begin to generate revenue and the other half to decreased R&D. Also, this will result in an overall reduction in total R&D spend of at least 20% to 25% next year. Total reductions will depend on how quickly we commercialize or cease operations. Finally, a few words on our cash and investments position which ended at $160 million for the quarter. We continue to see no effect on cash from the global economic uncertainty. In fact, our accounts receivable is the cleanest it has ever been, which is reflective of the strong position the desalination industry finds itself in despite the strange times. For now we continue to shift our corporate bond portfolio into cash and securities mature. As the future becomes more certain, we'll revisit our longer term plans. CapEx investments look to finish the year in the middle lower end of the $8 million to $10 million I guided this time last year. Our baseline CapEx for 2021 is planned at $5 million to $7 million. Now this baseline excludes any CapEx related to potential commercialization of the VorTeq, which will become clear, if and when we commercialize and we'll provide more clarity at that time. With that, let's move to the question-and-answer portion of our call. Thank you. ================================================================================ Questions and Answers -------------------------------------------------------------------------------- Operator [1] -------------------------------------------------------------------------------- Thank you. At this time, we will be conducting a question-and-answer session. (Operator Instructions) Our first question is from Pavel Molchanov with Raymond James. -------------------------------------------------------------------------------- Pavel Molchanov, [2] -------------------------------------------------------------------------------- I want to just review the guidance targets that you gave, make sure we all heard them right. Following 25% water revenue growth this year, it should slow to 10% growth next year, but then reaccelerate to 25% in '22. Is that correct? -------------------------------------------------------------------------------- Bob Mao, [3] -------------------------------------------------------------------------------- Correct. Yes, that is correct. -------------------------------------------------------------------------------- Pavel Molchanov, [4] -------------------------------------------------------------------------------- So what gives you the confidence that '22 will -- that will see the acceleration in the growth rate? Is it specific projects, specific geographies, specific customers? -------------------------------------------------------------------------------- Bob Mao, [5] -------------------------------------------------------------------------------- Actually, all of the above specific projects, specific geographies, and in fact, we already have some backlog going into 2022. So, it's not depending on macro market trends only, it is underground actually project by project, customer by customer. -------------------------------------------------------------------------------- Pavel Molchanov, [6] -------------------------------------------------------------------------------- And does it include retrofits of legacy plants? Or is it or are you only looking at greenfield new builds? -------------------------------------------------------------------------------- Bob Mao, [7] -------------------------------------------------------------------------------- Both. -------------------------------------------------------------------------------- Pavel Molchanov, [8] -------------------------------------------------------------------------------- My final question was about your comment about an industry that is being transformed by government regulation. And I'm sorry, if this is a silly question, but are you referring to the Oil & Gas industry or something else? -------------------------------------------------------------------------------- Bob Mao, [9] -------------------------------------------------------------------------------- We will clarify that next call as we are in the technical feasibility phase. -------------------------------------------------------------------------------- Operator [10] -------------------------------------------------------------------------------- Our next question is from Ryan Pfingst with B. Riley Securities. -------------------------------------------------------------------------------- Ryan James Pfingst, B. Riley Securities, Inc., Research Division - Associate [11] -------------------------------------------------------------------------------- In terms of your inventory of VorTeq equipment for the new single cartridge skin design, if the opportunity presented itself, could you simultaneously execute one well with Liberty and another with a different pressure pumper? If not, are you prioritizing the first attempted well with Liberty above all other options? Or if another interested party wanted to conduct the live well test before Liberty customers ready, would you move forward with that opportunity? -------------------------------------------------------------------------------- Bob Mao, [12] -------------------------------------------------------------------------------- We have enough inventories to those. So that pleasant opportunity always. -------------------------------------------------------------------------------- Ryan James Pfingst, B. Riley Securities, Inc., Research Division - Associate [13] -------------------------------------------------------------------------------- Okay. That's helpful. And then for hurdle numbers three on the path to commercialization, the buying of frac sand that the cartridge can process before needs to be repaired or replaced. How far along are you now towards your target? I know that by year-end, you aim to be at 50% with clear visibility, on raising a hundred percent. Could you give some insight on maybe what percentage you're at now or where you exited the third quarter? -------------------------------------------------------------------------------- Bob Mao, [14] -------------------------------------------------------------------------------- We are on track to reach those targets. -------------------------------------------------------------------------------- Ryan James Pfingst, B. Riley Securities, Inc., Research Division - Associate [15] -------------------------------------------------------------------------------- Okay. So on track for 100% visibility by your end. -------------------------------------------------------------------------------- Bob Mao, [16] -------------------------------------------------------------------------------- Yes. -------------------------------------------------------------------------------- Ryan James Pfingst, B. Riley Securities, Inc., Research Division - Associate [17] -------------------------------------------------------------------------------- Great. And then turning to the new PX derivative product developments, could you give some other examples of potential end users that you're investigating now? -------------------------------------------------------------------------------- Bob Mao, [18] -------------------------------------------------------------------------------- We shared particularly with zero mixing and that will open up additional end user into chemicals industry where no mixing is allowed at all. -------------------------------------------------------------------------------- Ryan James Pfingst, B. Riley Securities, Inc., Research Division - Associate [19] -------------------------------------------------------------------------------- All right. Thank you. And then maybe just one last one for Josh, could you please provide the third quarter breakdown for Water revenue by segments? -------------------------------------------------------------------------------- Joshua Ballard, Energy Recovery, Inc. - CFO [20] -------------------------------------------------------------------------------- Sure. It's 76% for the Mega-Projects, 15% for OEM and about 10% for aftermarket. -------------------------------------------------------------------------------- Operator [21] -------------------------------------------------------------------------------- (Operator Instructions) Our next question is from Ken Hirschberg, Private Investor. -------------------------------------------------------------------------------- Unidentified Analyst, [22] -------------------------------------------------------------------------------- Congratulations on the excellent quarter and all the progress you're making. Could you please give us an update on the commercialization of the IsoGen and IsoBoost? Thank you. -------------------------------------------------------------------------------- Bob Mao, [23] -------------------------------------------------------------------------------- On that one, we are in discussion with potential customers to deploy our standard product. And of course, our first project is fully in operation and the very happily accepted by our customers. So, what we look for here is for a standard product applicable to a larger base of customers rather doing individual almost custom-made projects. So, we're making progress. We expect to report more at the next earning call. -------------------------------------------------------------------------------- Unidentified Analyst, [24] -------------------------------------------------------------------------------- Is it for IsoGen and IsoBoost? -------------------------------------------------------------------------------- Bob Mao, [25] -------------------------------------------------------------------------------- Yes, both IsoGen and IsoBoost. Did I answer your question? -------------------------------------------------------------------------------- Unidentified Analyst, [26] -------------------------------------------------------------------------------- Yes, you did. Thank you very much. I appreciate that. -------------------------------------------------------------------------------- Bob Mao, [27] -------------------------------------------------------------------------------- Thank you. -------------------------------------------------------------------------------- Operator [28] -------------------------------------------------------------------------------- Ladies and gentlemen, we have reached the end of the question-and-answer session. Now, I'd like to turn the call back to James Siccardi for closing remarks. -------------------------------------------------------------------------------- James Siccardi, Energy Recovery, Inc. - VP of IR [29] -------------------------------------------------------------------------------- I want to thank everyone for joining us today. For your convenience, we've decided for our prepared remarks up on our website, you can access when you chance to get in. Thank you very much for joining us and we look forward to speaking with you again in March. Please be safe. Thank you. -------------------------------------------------------------------------------- Operator [30] -------------------------------------------------------------------------------- This concludes today's conference. We thank you for your participation. You may disconnect your lines at this time. Goodbye.

Excerpt from:
Edited Transcript of ERII.OQ earnings conference call or presentation 29-Oct-20 9:00pm GMT - Yahoo Finance

ReportHive added most up-to-date research on Withania Somnifera Extract Market Growth Factors, Applications, Regional Analysis, Key Players And Forecasts By 2026 to its huge collection of research reports.

Withania Somnifera Extract Market includes Overview, classification, industry value, price, cost and gross profit. It also covers types, enterprises and applications. To start with, analytical view to complete information of Withania Somnifera Extract market. It offers market view by regions with countries, development in Withania Somnifera Extract industry, opportunity with challenges, sales strategies, growth strategies and revenue analysis to include price. Withania Somnifera Extract Market report helps to analyses competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Withania Somnifera Extract Market Sales 2020 Industry Trend and Forecast 2026.

Withania Somnifera Extract Market Leading Players: Life Extension, Taos Herb Company, General Nutrition Centers, Jarrow Formulas, Huge Mountain, Organic India, The Vitamin Shoppe, NOW Foods, Solgar, Solgar, Piping Rock, Swanson

Request for Sample Report (Including COVID19 Impact Analysis, full TOC, Tables and Figures) of Withania Somnifera Extract Market

Withania Somnifera Extract Market impact Factors Analysis:Technology Progress/Risk, Substitutes Threat, Economic/Political Environmental modification. Technology Progress in connected trade, shopper Needs/Customer Preference modification.

The top geographical regions studied in this research report include North America, Europe, Asia-Pacific, Middle East, and Africa, South America and the rest of the world. The growing Withania Somnifera Extract Market and its progressive impact on the global economy is featured in this study. The competitive analysis of major Withania Somnifera Extract Industry players, market size analysis, dynamics, as well as the qualitative and numerical assessment, is conducted. The insights offered in this study will determine the potential of Withania Somnifera Extract Industry on global, regional and country-level paving the way for futuristic growth and investment feasibility.

The report covers exhaustive analysis on:

Market Segments Market Dynamics Market Size Supply & Demand Current Trends/Issues/Challenges Competition & Companies involved Technology Value Chain

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain in the Withania Somnifera Extract Market. The report Withania Somnifera Extract Market provide in-depth analysis of current market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on Withania Somnifera Extract Market segments and geographies.

This Withania Somnifera Extract Market report begins with a basic overview of the market. The analysis highlights the opportunity and Withania Somnifera Extract Market trends that are impacted the market. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Withania Somnifera Extract Market insight regarding the things which are driving and affecting the earnings of the market. The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Market Segmentation: By TypeCapsule, Liquid

Market Segmentation: By ApplicationHealth Products, Drug

Quantifiable data:

Market Data Breakdown by Key Geography, Type & Application / End-User By type (past and forecast) Withania Somnifera Extract Market: Specific Applications Sales and Growth Rates (Historical & Forecast) Withania Somnifera Extract Market revenue and growth rate by the market (history and forecast) Withania Somnifera Extract Market size and growth rate, application and type (past and forecast)

>>> To get Incredible Discounts on this Premium Report, Click Here @ https://www.reporthive.com/2537898/check_discount

Highlights of TOC:

Report Overview: It includes major players of the global Withania Somnifera Extract Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends: This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Withania Somnifera Extract Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Withania Somnifera Extract Market are discussed.

Market Share by Manufacturers: Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type: This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application: Besides an overview of the global Withania Somnifera Extract Market by application, it gives a study on the consumption in the global Withania Somnifera Extract Market by application.

Production by Region: Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region: This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles: Almost all leading players of the global Withania Somnifera Extract Market are profiled in this section. The analysts have provided information about their recent developments in the global Withania Somnifera Extract Market, products, revenue, production, business, and company.

Market Forecast by Production: The production and production value forecasts included in this section are for the global Withania Somnifera Extract Market as well as for key regional markets.

Market Forecast by Consumption: The consumption and consumption value forecasts included in this section are for the global Withania Somnifera Extract Market as well as for key regional markets.

Value Chain and Sales Analysis: It deeply analyzes customers, distributors, sales channels, and value chain of the global Withania Somnifera Extract Market.

Key Findings: This section gives a quick look at important findings of the research study.

>>> Make an enquiry before buying this report @ https://www.reporthive.com/2537898/enquiry_before_purchase

Why Report Hive Research:

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc.

Contact Us:

Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesWebsite: https://www.reporthive.comEmail: [emailprotected]Phone: +1 312-604-7084

Life Extension, Taos Herb Company, General Nutrition Centers, Jarrow Formulas, Huge Mountain, Organic India, The Vitamin Shoppe, NOW Foods, Solgar, Solgar, Piping Rock, Swanson, Withania Somnifera Extract, Withania Somnifera Extract Industry, Withania Somnifera Extract Market, Withania Somnifera Extract Market 2020, Withania Somnifera Extract Market analysis, Withania Somnifera Extract Market Analysis in Developed Countries, Withania Somnifera Extract Market by Application, Withania Somnifera Extract Market by Type, Withania Somnifera Extract Market comprehensive analysis, Withania Somnifera Extract Market comprehensive report, Withania Somnifera Extract Market Development, Withania Somnifera Extract Market Evolving Opportunities With Top Industry Experts, Withania Somnifera Extract Market forecast, Withania Somnifera Extract Market Forecast to 2025, Withania Somnifera Extract Market Forecast to 2026, Withania Somnifera Extract Market Forecast to 2027, Withania Somnifera Extract Market Future Innovation, Withania Somnifera Extract Market Future Trends, Withania Somnifera Extract Market Google News, Withania Somnifera Extract Market Growing Demand and Growth Opportunity, Withania Somnifera Extract market growth, Withania Somnifera Extract Market in Asia, Withania Somnifera Extract Market in Australia, Withania Somnifera Extract Market in Canada, Withania Somnifera Extract Market in Europe, Withania Somnifera Extract Market in France, Withania Somnifera Extract Market in Germany, Withania Somnifera Extract Market in Israel, Withania Somnifera Extract Market in Japan, Withania Somnifera Extract Market in Key Countries, Withania Somnifera Extract Market in Korea, Withania Somnifera Extract Market in United Kingdom, Withania Somnifera Extract Market in United States, Withania Somnifera Extract Market insights, Withania Somnifera Extract Market is Booming, Withania Somnifera Extract Market is Emerging Industry in Developing Countries, Withania Somnifera Extract Market Latest Report, Withania Somnifera Extract Market opportunities, Withania Somnifera Extract market report, Withania Somnifera Extract market research, Withania Somnifera Extract Market Research report, Withania Somnifera Extract Market research study, Withania Somnifera Extract Market Rising Trends, Withania Somnifera Extract Market Size in United States, Withania Somnifera Extract market strategy, Withania Somnifera Extract Market SWOT Analysis, Withania Somnifera Extract Market Updates

Read more from the original source:
Comprehensive Report on Withania Somnifera Extract Market by global COVID-19 impact analysis, industry trends, business strategies, opportunities and...

With the advancing electronics and semiconductors industry, the demand for cold plasma (CP) has been on the rise. While the demand for applications such as coating and finishing, surface treatment, adhesion, and etching, associated with printed circuit boards (PCBs) is soaring, the market for cold plasma is also expected to benefit from a slew of applications arising in other end use industries. Moreover, increasing applications in food safety will also push the market for cold plasma further, over the next few years. As depicted in a recent research report published by Persistence Market Research (PMR), the US$ 1.4 Bn global cold plasma market is presumed to observe stellar growth over an eight-year projection period. Between 2018 and 2026, the cold plasma market will possibly expand at a CAGR of 16.3%, as indicated by PMRs globalcold plasma marketreport.

The potential applications of cold plasma technology traverse a wide range, including the extension of product shelf-life and environmental sustainability. Such applications have been attracting the scientific community towards cold plasma research, over the years. The CP technique has already been proven to be an economic and environment-friendly technology in the textile industry. Textile companies are increasingly adopting cold plasma technique in an effort to deliver improved textile finishing.

Request For Report[emailprotected]https://www.persistencemarketresearch.com/samples/17053

Cold Plasma Technology Soon to Transform Wound Treatment Space

While cold plasma applications in sterilization and disinfection are currently accounting for maximum revenue in the cold plasma market, rapidly emerging applications in wound healing and adhesion will reportedly create lucrative opportunities for stakeholders.

Coldplasmatech GmbH, a German company, is looking forward to introduce a novel CP technology that could potentially revolutionize the wound care treatment platform, especially in emergency rooms in hospitals. The CP technology involves a patch of cold plasma made of silicone (as a part of the wound dressing), which can be used in treatment of chronic wound infections with the help of UV radiations and ions. This technology is presumed to provide a high-tech, efficient alternative to antibiotics, considering its ability to accelerate the wound healing process. If the trials based on the application of the cold plasma technology in faster wound healing deliver convincing and viable results, industry experts predict that the CP technology could become a widespread method for treatment of chronic wounds and infection, in near future.

Cold Plasma Technology to Win Preference over Conventional Processing Technologies

Among all end use industries generating demand for cold plasma, electronics and semiconductors are foreseen to reign supreme. Whereas, rising demand for cold plasma is expected to uplift the prospects for cold plasma in food processing and packaging, and plastics and polymers industries.

Advanced cold plasma technology is being widely used in the in-package decontamination of fresh foods. Shelf-life extension will also remain a key objective of fresh food industry participants, using cold plasma as a unit technology. With successful trials of the regulation of contaminants mediated by cold plasma, the applications of cold plasma in agriculture sector are expected to surge in near future. Additionally, research shows that it is possible to degrade the chemical residues of pesticides to relatively lesser toxic and safer structures, by using cold plasma. It also offers an excellent alternative to conventional fertilizers and pesticides.

As far as the processed and packaged food industry is concerned, cold plasma has been proven to hold immense potential as a safe and eco-friendly alternative to traditionally used chemical processes. Moreover, it is considered as a novel non-thermal technology for processing of foods, especially fruits and vegetables, and poultry and meat prominently attributed to the non-thermal nature, versatile design, and economic pricing of cold plasma. Research findings also confirm that cold plasma treatment poses no or minimal impact on a products chemical, physical, sensory, and nutritional attributes. However, it still remains to be seen whether cold plasma processing will completely replace the traditionally used processing technologies, as the research outcome is still in the pipeline and demands more extensive research in order to reach its potential.

Request Report[emailprotected]https://www.persistencemarketresearch.com/methodology/17053

Company Profiles

For in-depth competitive analysis, buy[emailprotected]https://www.persistencemarketresearch.com/checkout/17053

ABOUT US:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

CONTACT:

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

USA Canada Toll Free: 800-961-0353

Excerpt from:
The global Cold Plasma Market to go steady between 2018 and 2026 - The Think Curiouser

DetailsCategory: Small MoleculesPublished on Friday, 30 October 2020 17:39Hits: 210

- Enrollment to cease immediately; topline data anticipated in H1 2021-

TEL AVIV, Israel I October 30, 2020 I BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.

At a meeting of the study's independent Data Monitoring Committee (DMC), a planned interim analysis of the study's primary endpoint was conducted independently by the DMC. Based on the statistically significant evidence favoring treatment with motixafortide, the DMC issued a recommendation to the Company that patient enrollment may be ceased immediately, without the need to recruit all 177 patients originally planned for the study.

In accordance with the DMC's recommendation, study enrollment is now complete at 122 patients. Full results for the study, including secondary and exploratory efficacy endpoints, as well as extended safety data, will be announced after the last patient enrolled reaches 100 days of follow-up post-transplantation, which is expected to occur in the first half of 2021.

"The compelling results of this planned interim analysis are a very significant milestone for our Company, as our SCM program is the Company's most efficient path to registration for motixafortide," stated Philip Serlin, Chief Executive Officer of BioLineRx. "Stem cell mobilization represents a significant unmet medical need in multiple myeloma, as between 50% and 70% of patients are poor mobilizers. We eagerly await the final results of the study, expected in the first half of next year, which we hope will support our goal of changing the treatment paradigm in autologous stem-cell mobilization, thus positioning motixafortide in combination with G-CSF as the new standard of care in this indication."

The GENESIS trial was initiated in December 2017. GENESIS is a randomized, placebo-controlled, multicenter study, evaluating the safety, tolerability and efficacy of motixafortide and G-CSF, compared to placebo and G-CSF, for the mobilization of HSCs for autologous transplantation in multiple myeloma patients. The primary objective of the study is to demonstrate that only one dose of motixafortide on top of G-CSF is superior to G-CSF alone in the ability to mobilize 6x106 CD34+ cells in up to two apheresis sessions. Secondary objectives include time to engraftment of neutrophils and platelets and durability of engraftment, as well as other efficacy and safety parameters.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company's lead program, motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA and chemotherapy under a collaboration agreement with MSD. Motixafortide is also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook,Twitter, and LinkedIn

SOURCE: BioLineRx

Here is the original post:
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization | Small...

WASHINGTON, Oct. 26, 2020 /PRNewswire/ --Despite the increasing use and promise of hematopoietic cell transplantation (HCT) as curative therapy for children with cancer and other life-threatening diseases, new research suggests that children transplanted for cancer are more likely to die from treatment-related complications if they live in poorer neighborhoods. The study, published today in the journal Blood, also found that having Medicaid versus private insurance, another marker of poverty, was associated with a higher chance of dying. Researchers say the results underscore the need to better understand and mitigate the effects of poverty and other social determinants of health on pediatric cancer care.

Hematopoietic cell transplantation, also called stem cell or bone marrow transplantation, is a treatment option for patients with blood cancers such as leukemia or lymphoma, as well as certain non-malignant conditions such as sickle cell disease or immunodeficiencies. It is only accessible at some medical centers. Together with radiation therapy or chemotherapy, HCT is designed to increase the chance of eliminating the cancerous or abnormal blood cells, and of restoring normal blood cell production.

The data revealed that children under the age of 18 with cancer who live in communities with high poverty rates had a 34% greater risk of treatment-related mortality following HCT compared with children in low-poverty areas. Even after adjusting for a child's disease and transplant-related factors, the data revealed children on Medicaid had a 23% greater risk of dying from any cause within five years of undergoing HCT and a 28% greater risk of treatment-related mortality when compared to children with private insurance.

"Our study shows that even after children with cancer have successfully accessed this high-resource treatment at specialized medical centers, those who are exposed to poverty are still at higher risk of dying of complications after treatment and of dying overall," said lead author Kira Bona, MD, MPH, Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center. "Simply providing the highest quality complex medical care to children who are vulnerable from a social perspective is inadequate if our goal is to cure every child with cancer."

One in five children in the U.S. lives in a household with an income below the federal poverty level. While previous studies have shown an association between household poverty and poorer outcomes in HCT procedures generally, there are limited data on how poverty influences the success of HCT in children specifically.

Dr. Bona and her team sought to fill this gap by reviewing outcomes data for pediatric allogeneic transplant recipients from the Center for International Blood and Marrow Transplant Research Database, the largest available repository of HCT outcomes. The researchers looked at two cohorts of patients: 2,053 children with malignant disease and 1,696 children with non-malignant disease, who underwent a first HCT between 2006 and 2015. Neighborhood poverty exposure was defined according to U.S. Census definitions as living within a ZIP code in which 20% or more of the residents live below 100% of the Federal Poverty Level. They also stratified patients by type of insurance and used Medicaid as a proxy measure for household level poverty. The researchers looked at pediatric patients' overall survival defined as the time from HCT until death from any cause, as well as relapse, transplant-related mortality, acute and chronic graft-versus-host disease, and infection in the first 100 days following HCT.

Interestingly, neighborhood poverty or having Medicaid insurance did not seem to affect outcomes, including overall survival, relapse, or infection, among children transplanted for non-malignant diseases such as sickle cell disease. Dr. Bona said the study does not explain why this might be and more research is needed; however, it is possible that physicians and families of children with non-malignant conditions who face social health challenges may elect to avoid intensive HCT procedures.

One study limitation is its reliance on proxy measures of household poverty (ZIP code and Medicaid insurance) that do not provide insight into specific aspects of an individual child's socioeconomic exposures and the home environment in which they live that may interfere with their ability to navigate the health care system. Dr. Bona says researchers and clinicians have historically not considered social determinants of health as being as important as biological variables in specialized cancer care and so have not collected data on these factors as part of research. She says this is a missed opportunity.

"We as a field need to recognize that non-biological variables such as your exposure to poverty and other social determinants of health matter just as much as many of the biological variables we pay close attention to when thinking about outcomes for children, and these variables must be collected systematically for research if we want to optimize the care and outcomes of the children we serve," Dr. Bona said.

If future studies could collect more nuanced measures of poverty such as household material hardship (e.g., food insecurity, access to heat and electricity, housing insecurity, transportation insecurity) or language barriers, targeted interventions in the form of assistance programs could potentially help mitigate social hardships and improve the overall care of children with cancer.

Blood(www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).

SOURCE American Society of Hematology/Blood Journal

http://www.bloodjournal.org

Go here to read the rest:
Study: Poverty Linked to Higher Risk of Death Among Children with Cancer Undergoing Stem Cell Transplantation - PRNewswire

An 11-year-old girl is in urgent need of a bone marrow transplant after being diagnosed with a rare, life-threatening condition.

Arya Lloyd, who was born in the Leicester Royal Infirmary, started to complain of abdominal pain and aches in her back and ribs during the summer.

Her father, Geraint said "she had always been fit and healthy" and did well in sports. So it was a shock to him and his wife, Arya's mother Brundha, when she was diagnosed with aplastic anaemia in late July this year.

Aplastic anaemia, also known as bone marrow failure, is a rare disease affecting the blood whereby the bone marrow and stem cells do not produce enough blood cells.

Arya then went on to have two bone marrow biopsies after her diagnosis.

"Her blood count continued to drop and that's why it is so important to get a donor match," Geraint said.

But finding a match will be a challenge. Arya, whose mother is of Indian heritage and father is Caucasian, will wait longer to find a suitable match due to her dual heritage.

Currently, those of Asian, Black or mixed ethnic background have a 20 per cent chance of finding the best possible match from an unrelated donor, compared with the 70 per cent chance of finding a match for Caucasian patients.

Arya and her parents, who a currently live in Cambridge are "staying positive" while Arya undergoes immunosuppressive treatment at St Mary's Hospital in Paddington.

Geraint told LeicestershireLive: She has been really brave and she just gets on with it. I wish it was me rather than her going through all this but she's optimistic."

The 11-year-old schoolgirl is expected to be discharged from the hospital this week and has spent her time keeping in touch with friends and catching up with homework when she can.

It has now been 22 days since she was admitted to hospital where she has been able to stay with her mother. Due to Covid-19 restrictions, the pair have had to stay in an isolated room and unable to see Geraint who has kept in touch through video calls.

"It's been really difficult, our whole world has been turned upside-down but we need to be optimistic and find a match," Geraint said.

The family is now urging people to come forward and join the bone marrow donor register.

"It's very urgent and so important that particularly people of Indian and mixed heritage join the register as they are hugely underrepresented," Geraint said.

So far, no suitable match has been found for Arya and it will take several months to determine the effects of the treatment she is currently having.

Following the immunosuppressive treatment, Arya will be infection-prone and have to be careful to avoid any trauma or injury due to her low blood count. This also leaves her in the category of people who are at higher risk from Covid-19.

While Arya and her family continue to adjust and stay positive, they need your help.

Joining the bone marrow donor register is simple and can be done from home by ordering a swab kit that is then sent back and analysed.

You can find out more about Arya's story and how to join the register at http://www.dkms.org.uk/en/arya.

See more here:
11-year-old urgently needs a bone marrow transplant after being diagnosed with life-threatening condition - Leicestershire Live

Blood cancer is a disorder that affects the production as well as the normal functioning of blood cells. The process of normal blood cell development is disturbed because of the uncontrolled growth of abnormal blood cells. These abnormal or cancerous cells disrupt the normal functions of blood components such as preventing bleeding and defending infections.

Blood Cancer (Haematopoietic malignancies) is one of the top 10 cancers in India and as per the latest Cancer Report of ICMR, it is estimated that by 2025 nearly 1.38 lakh people would be affected. Currently, around 1.25 lakh people are suffering from the disease which constitutes 9% of total cancers in the country.

While speaking about blood cancer, Dr Divya Bansal, Consultant - Clinical Hematology and Stem Cell Transplant, HCMCT Manipal Hospitals, New Delhi, said, "Blood is a liquid medium present throughout the body and not confined to a defined area, which makes blood cancers and their treatment very different from solid-organ cancers. There is a limited role of surgery and radiation therapy in the treatment of blood cancers, as they are thermosensitive."

She continued, "Chemotherapy treatment for blood cancers is much more intense in comparison to solid cancers and hence, their side effects. Also, the staging of blood cancers is very different from solid cancers and concept of metastasis is not applicable for blood cancers."

"In the case of blood cancers, prognostic risk stratification is important. Bone marrow transplant has a limited role in solid cancers but remains the curative treatment for blood cancers. This difference has actually led to the development of a completely different speciality for treatment of blood cancers i.e. Haemato-oncology, all over the world," Dr Divya Bansal added.

Meanwhile, in order for us to understand the types of blood cancers, its symptoms and treatment, Dr Divya Bansal carefully explained each one and helped us list them out.

Take a look.

Types of blood cancers

Leukaemia

This is caused by the fast production of abnormal white blood cells, and these abnormal are seen in blood and the bone marrow. A large number of abnormal WBCs are unable to defend infections.

Lymphoma

This is a type of blood cancer that involves the lymphatic system. Abnormal lymphocytes turn into lymphoma cells that multiply and get accumulated in the lymph nodes. Gradually, these cancer cells impair the immune system.

Myeloma

This affects the plasma cells, the cells that produce antibodies against disease in the body. Myeloma cells disturb the normal development of antibodies and make the body susceptible to infection.

Symptoms

- Fever- Weight loss- Loss of appetite- Bony pains- Bleeding from any sites- Generalised weakness and fatigue- Night sweats- Nodular swelling around the neck, axilla or groin- Abdominal swelling

Diagnosis

One can get the disease diagnosed with the help of a blood test, bone marrow aspiration, and biopsy. In cases of lymphoma, one must opt for a lymph node biopsy. Other options include PET-CT, specialized tests such as Flowcytometry or Immunohistochemistry, Fluorescent in situ hybridization (FISH), Karyotyping and Next-generation sequencing (NGS) which is the latest technique of diagnosing and risk stratification of blood cancers.

Treatment

Chemotherapy

An oral or injectable drug that travels in the bloodstream throughout the body and kills the cancer cells. It damages cancer cells and stops division and growth of it, leading to their death.

Immunotherapy

It refers to agents that use the bodys immune system to help fight diseases such as blood cancer. It can work directly with your bodys immune system to stop or slow the growth of cancer cells. Biologic therapies include substances made by the body or in a lab. Cytokines, Gene therapy, and Immunomodulators, and Monoclonal antibodies are the main types of immunotherapy.

Targeted therapy

Therapies that target a certain genetic mutation known to occur in a specific blood cancer is called targeted therapy. Here, we target a protein that is present in cancer cells due to mutation. As soon as a mutation is identified, we can develop a treatment to target that target. Destroying cancer cells is the main aim of this therapy.

Bone Marrow Transplantation (BMT)

It is a procedure where a damaged or non-functional bone marrow cells are replaced by healthy multipotent hematopoietic stem cells.

Overall, BMT remains the only curative treatment for most of the blood cancers. There are two types of bone marrow transplant procedure used in the treatment of blood cancers -- Autologous BMT, when patient's own stem cells are infused back after high dose chemotherapy, and, Allogenic BMT, when the source of stem cells is a healthy donor, either related or unrelated.

A few blood cancers if treated promptly and effectively can be managed well and even cured.

Examples of blood cancers which can be cured include Acute Promyelocytic leukaemia, Chronic myeloid leukaemia, Hairy cell leukaemia, and Paediatric Acute lymphoblastic leukaemia.

Continue reading here:
Know all about types of blood cancer, its symptoms, diagnosis and treatment - DNA India

The lymphoid organs purpose is to provide immunity for the body. This second article in a six-part series explains the primary and secondary lymphoid organs and their clinical significance and structure. It comes with a self-assessment enabling you to test your knowledge after reading it

This article is the second in a six-part series about the lymphatic system. It discusses the role of the lymphoid organs, which is to develop and provide immunity for the body. The primary lymphoid organs are the red bone marrow, in which blood and immune cells are produced, and the thymus, where T-lymphocytes mature. The lymph nodes and spleen are the major secondary lymphoid organs; they filter out pathogens and maintain the population of mature lymphocytes.

Citation: Nigam Y, Knight J (2020) The lymphatic system 2: structure and function of the lymphoid organs. Nursing Times [online]; 116: 11, 44-48.

Authors: Yamni Nigam is professor in biomedical science; John Knight is associate professor in biomedical science; both at the College of Human and Health Sciences, Swansea University.

This article discusses the major lymphoid organs and their role in developing and providing immunity for the body. The lymphoid organs include the red bone marrow, thymus, spleen and clusters of lymph nodes (Fig 1). They have many functional roles in the body, most notably:

The red bone marrow and thymus are considered to be primary lymphoid organs, because the majority of immune cells originate in them.

Bone marrow is a soft, gelatinous tissue present in the central cavity of long bones such as the femur and humerus. Blood cells and immune cells arise from the bone marrow; they develop from immature stem cells (haemocytoblasts), which follow distinct developmental pathways to become either erythrocytes, leucocytes or platelets. Stem cells rapidly multiply to make billions of blood cells each day; this process is known as haematopoiesis and is outlined in Fig 2.

To ensure there is a continuous production and differentiation of blood cells to replace those lost to function or age, haematopoietic stem cells are present through adulthood. In the embryo, blood cells are initially made in the yolk sac but, as development of the embryo proceeds, this function is taken over by the spleen, lymph nodes and liver. Later in gestation, the bone marrow takes over most haematopoietic functions so that, at birth, the whole skeleton is filled with red bone marrow.

Red bone marrow produces all erythrocytes, leucocytes and platelets. Haematopoietic stem cells in the bone marrow follow either the myeloid or lymphoid lineages to create distinct blood cells (Fig2); these include myeloid progenitor cells (monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, dendritic cells and platelets), and lymphoid progenitor cells (T-lymphocytes, B-lymphocytes and natural killer cells).

Some lymphoid cells (lymphocytes) begin life in the red bone marrow and become fully formed in the lymphatic organs, including the thymus, spleen and lymph nodes. As puberty is reached and growth slows down, physiological conversion occurs, changing red bone marrow to yellow bone marrow. This entire process is completed by the age of 25years, when red bone marrow distribution shows its adult pattern in the bones.

The pattern is characterised by:

However, under particular conditions, such as severe blood loss or fever, the yellow marrow may revert back to red marrow (Malkiewicz and Dziedzic 2012).

Any disease or disorder that poses a threat to the bone marrow can affect many body systems, especially if it prevents stem cells from turning into essential cells. Those known to damage the marrows productive ability and destroy stem cells include:

A growing number of diseases can be treated with a bone marrow transplant or haematopoietic stem cell transfer; this is often achieved by harvesting suitable donor stem cells from the posterior iliac crests of the hip bone, where the concentration of red bone marrow is highest.

The thymus gland is a bi-lobed, pinkish-grey organ located just above the heart in the mediastinum, where it rests below the sternum (breastbone). Structurally, the thymus resembles a small bow tie, which gradually atrophies (shrinks) with age. In pre-pubescents, the thymus is a relatively large and very active organ that, typically, weighs around 40g, but in a middle-aged adult it may have shrunk sufficiently to be difficult to locate. By 20 years of age, the thymus is 50% smaller than it was at birth, and by 60years of age it has shrunk to a sixth of its original size (Bilder, 2016); this is called thymic involution

Each of the two lobes of the thymus is surrounded by a capsule, within which are numerous small lobules typically measuring 2-3mm in width which are held together by loose connective tissue. Each lobule consists of follicles that are composed of a framework of thyomsin-secreting epithelial cells and a population of T-lymphocytes; these cells are commonly referred to as T-cells (the T denotes their origin as mature cells from the thymus). Lobules have two distinct areas:

In addition to being a major lymphoid organ, the thymus is also recognised as part of the endocrine system because it secretes a family of hormones collectively referred to as thymosin; this is a group of several structurally related hormones secreted by the thymic epithelial cells. These hormones are essential for normal immune function and many members of the thymosin family are used therapeutically to treat cancers, infections and diseases such as multiple sclerosis (Severa et al, 2019).

T-cells originate as haematopoietic stem cells from the red bone marrow (Fig2). A population of these haematopoietic stem cells infiltrate the thymus, dividing further within the cortical regions of the lobules then migrating into the medullary regions to mature into active T-cells; this process of T-cell maturation is controlled by the hormone thymosin. A proportion of these mature T-cells continually migrate from the thymus into the blood and other lymphoid organs (spleen and lymph nodes), where they play a major role in the bodys specific immune responses (which will be discussed in detail in part 3 of this series). The importance of these cells is apparent in patients who have depleted T-cell populations, such as those infected with HIV.

One of the most important functions of the thymus is programming T-cells to recognise self antigens through a process called thymic education. This process allows mature T-cells to distinguish foreign, and therefore potentially pathogenic, material from antigens that belong to the body. It has been demonstrated that removal of the thymus may lead to an increase in autoimmune diseases, as this ability to recognise self is diminished (Sherer et al, 1999).

Diseases of the thymus include thymic cancer and myasthenia gravis (MG). MG occurs when the thymus produces antibodies that block or destroy the muscle-receptor sites, causing the muscles to become weak and easily tired. It most commonly affects muscles that control the eyes and eyelids, resulting in droopy eyelids and difficulty making facial expressions; chewing, swallowing and speaking also become difficult. MG can affect people of any age, but typically starts in women aged <40years and men aged >60years.

In most cases of either MG or thymic cancer, thymectomy is recommended. Patients who have had a thymectomy may develop an immunodeficiency known as Good syndrome, which increases their susceptibility to bacterial, fungal and viral opportunistic pathogens; this condition is, however, relatively rare.

The spleen and lymph nodes are two major secondary lymphoid organs that play key roles in:

When foreign antigens reach these organs, they initiate lymphocyte activation and subsequent clonal expansion and maturation of these important white blood cells. Mature lymphocytes can then leave the secondary organs to enter the circulation, or travel to other areas, and target foreign antigens.

The spleen is the largest lymphoid organ. Situated in the upper left hypochondriac region of the abdominal cavity, between the diaphragm and the fundus of the stomach, it primarily functions as a filter for the blood, bringing it into close contact with scavenging phagocytes (white blood cells in the spleen that will seek out and eat any pathogens in the blood) and lymphocytes.

Due to its extensive vascularisation, the spleen is a dark-purplish oval-shaped organ; in adults it is approximately 12cm long, 7cm wide and weighs around 150g. However, the size of the spleen can vary with circumstance: it diminishes in starvation, after heavy exercise and following severe haemorrhage (Gujar et al, 2017), and recent investigations indicate an increase in size in well-fed individuals and during the ingestion of food (Garnitschnig et al, 2020).

The spleen (Fig3) is enclosed in a dense, fibro-elastic capsule that protrudes into the organ as trabeculae; these trabeculae constitute the organs framework. Blood enters the spleen from the splenic artery and leaves via the splenic vein, both of which are at the hilum; the splenic vein eventually becomes a tributary of the hepatic portal vein.

The spleen is made up of two regions:

White pulp is a mass of germinal centres of dividing B-lymphocytes (B-cells), surrounded by T-cells and accessory cells, including macrophages and dendritic cells; these cells are arranged as lymphatic nodules around branches of the splenic artery. As blood flows into the spleen via the splenic artery, it enters smaller, central arteries of the white pulp, eventually reaching the red pulp. The red pulp is a spongy tissue, accounting for 75% of the splenic volume (Pivkin et al, 2016); it consists of blood-filled venous sinuses and splenic cords.

Splenic cords are made up of red and white blood cells and plasma cells (antibody-producing B-cells); therefore, the red pulp primarily functions as a filtration system for the blood, whereas the white pulp is where adaptive T- and B-cell responses are mounted. The colour of the white pulp is derived from the closely packed lymphocytes and the red pulps colour is due to high numbers of erythrocytes (Stewart and McKenzie, 2002).

The spleen has three major functions:

The spleens main immunological function is to remove micro-organisms from circulation. The lymphatic nodules are arranged as sleeves around the blood vessels, bringing blood into the spleen. Within the white pulp are splenic nodules called Malpighian corpuscles, which are rich in B-cells, so this portion of lymphoid tissue is quick to respond to foreign antigenic stimulation by producing antibodies. The walls of the meshwork of sinuses in the red pulp also contain phagocytes that engulf foreign particles and cell debris, effectively filtering and removing them from circulation.

In the spleens destruction of old and senescent red blood cells, they are digested by phagocytic macrophages in the red pulp. The haemoglobin is then split apart into haem and globin. The globin is broken down into its constituent amino acids, which can be utilised in the synthesis of a new protein. Haem consists of an iron atom surrounded four non-iron (pyrrole) rings.

The iron is removed and transported to be stored as ferritin, then reused to make new haemoglobin in the red bone marrow; macrophages convert the pyrrole rings into the green pigment biliverdin and then into the yellow pigment bilirubin. Both are transported to the liver bound to plasma albumin. Bilirubin, the more toxic pigment, is conjugated in the liver to form a less toxic compound, which is excreted in bile.

The red pulp partly serves to store a large reserve of the bodys platelets up to a third of the total platelet supply. In some animals particularly athletic mammals such as horses, greyhounds and foxes the spleen is also an important reservoir of blood, which is released into circulation during times of stress to improve aerobic performance. In humans, however, the spleen contributes only a small percentage of blood cells into active circulation under physiological stress; the total stored blood volume is believed to be only 200-250ml (Bakovic et al, 2005). The capsule of the spleen may contract following haemorrhage, releasing this reserve into circulation in the body.

The spleen also plays a minor role in haematopoiesis: usually occuring in foetuses of up to five months gestation, erythrocytes, along with the bone marrow, are produced by the spleen.

As the spleen is the largest collection of lymphoid tissue in the body, infections that cause white blood cell proliferation and antigenic stimulation may cause germinal centres in the organ to expand, resulting in its enlargement (splenomegaly). This happens in many diseases for example, malaria, cirrhosis and leukaemia. The spleen is not usually palpable, but an enlarged spleen is palpable during deep inspiration. Enlargement may also be caused by any obstruction in blood flow, for example in the hepatic portal vein.

The anatomical position of the spleen coincides with the left tenth rib. Given its proximity to the abdominal wall, it is one of the most commonly injured organs in blunt abdominal trauma. The spleen is a fragile organ and, due to its highly vascularised nature, any injury causing rupture will rapidly lead to severe intraperitoneal haemorrhage; death may result due to massive blood loss and shock.

A moderate splenic injury may be managed conservatively, but an extensively burst or ruptured spleen may be treated by complete and prompt removal (splenectomy). However, current data supports successful non-operative management of many traumatic splenic injuries, with the intention of reducing the need for complete removal (Armstrong et al, 2019).

Patients being treated for certain malignant diseases may also require a partial or total splenectomy and, although other structures such as the bone marrow and liver can take over some of the functions that are usually carried out by the spleen, such patients may be at increased risk of infection. With an overwhelming post-splenectomy infection, there is also an increased risk of sepsis, which is associated with significant morbidity and mortality. Infection is usually with encapsulated pathogens, including Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis. Clinical guidelines to help reduce the risk of infection advocate education about infection prevention, vaccination and antibiotic prophylaxis (Arnott et al, 2018).

Swollen lymph nodes and a fever are sure signs that the body is mounting an effective immune response against an offending pathogen

Lymph nodes vary in size and shape, but are typically bean-shaped structures found clustered at specific locations throughout the body. Although their size varies, each node has a characteristic internal structure (Fig4).

The central portions of the lymph node are essential to its function; here, there are large numbers of fixed macrophages, which phagocytose foreign material such as bacteria on contact, and populations of B- and T-cells. Lymph nodes are crucial to most antibody-mediated immune responses: when the phagocytic macrophages trap pathogenic material, that material is presented to the lymphocytes so antibodies can be generated.

Each lymph node is supplied by one or more afferent lymphatic vessels, which deliver crude, unmodified lymph directly from neighbouring tissues. A healthy, fully functioning node removes the majority of pathogens from the lymph before the fluid leaves via one or more efferent lymphatic vessels. In addition to its lymphatic supply, each lymph node is supplied with blood via a small artery; the artery delivers a variety of leucocytes, which populate the inner regions of the node.

When infection is present, the lymph nodes become increasingly metabolically active and their oxygen requirements increase. A small vein carries deoxygenated blood away from each node and returns it to the major veins. In times of infection, this venous blood may carry a variety of chemical messengers (cytokines) that are produced by the resident leucocytes in the nodes. These cytokines act as general warning signals, alerting the body to the potential threat and activating a variety of specific immune reactions.

The structure of a lymph node is not unlike that of the spleen. Each lymph node is divided into several regions:

During infection, antibody-producing B-cells begin to proliferate in the germinal centres, causing the affected lymph nodes to enlarge and become palpable and tender. Some of the cytokines released are pyrogenic (meaning they cause fever) and act directly on the thermoregulatory centre in the hypothalamus to increase body temperature. As the majority of human pathogens divide optimally at around 37C, this increase in body temperature serves to slow down bacterial replication, allowing the infection to be dealt with more efficiently by the immune system. Swollen lymph nodes and a fever are both sure signs that the body is mounting an effective immune response against the offending pathogen; this will be discussed in more detail in part 3 of this series.

Other types of lymphatic tissue also exist. Mucosa-associated lymphoid tissue (MALT) is positioned to protect the respiratory and gastrointestinal tracts from invasion by microbes. The following are made up of MALT:

The tonsils are aggregates of lymphatic tissue strategically located to prevent foreign material and pathogens from entering the body. The palatine tonsils are in the pharynx, the lingual tonsils in the oral cavity and the pharyngeal tonsils (adenoids) are at the back of the nasal cavity; as a result of this, the tonsils themselves are at high risk of infection and inflammation (tonsillitis). This will also be discussed further in part 3.

Armstrong RA et al (2019) Successful non-operative management of haemodynamically unstable traumatic splenic injuries: 4-year case series in a UK major trauma centre. European Journal of Trauma and Emergency Surgery; 45: 5, 933-938.

Arnott A et al (2018) A registry for patients with asplenia/hyposplenism reduces the risk of infections with encapsulated organisms. Clinical Infectious Diseases; 67: 4, 557-561.

Bakovi D et al (2005) Effect of human splenic contraction on variation in circulating blood cell counts. Clinical and Experimental Pharmacology and Physiology; 32: 11, 944-951.

Bilder G (2016) Human Biological Aggin: From Macromolecules to Organ Systems. Wiley.

Garnitschnig L et al (2020) Postprandial dynamics of splenic volume in healthy volunteers. Physiological Reports; 8: 2, e14319.

Gujar S et al (2017) A cadaveric study of human spleen and its clinical significance. National Journal of Clinical Anatomy; 6: 1, 35-41.

Makiewicz A, Dziedzic M (2012) Bone marrow reconversion: imaging of physiological changes in bone marrow. Polish Journal of Radiology; 77: 4, 45-50.

Pivkin IV et al (2016) Biomechanics of red blood cells in human spleen and consequences for physiology and disease. Proceedings of the National Academy of Sciences of the United States of America; 113: 28, 7804-7809.

Severa M et al (2019) Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application. Multiple Sclerosis and Related Disorders; 27: 52-60.

Sherer Y et al (1999) The dual relationship between thymectomy and autoimmunity: the kaleidoscope of autoimmune disease. In: Paul S (ed) Autoimmune Reactions. Contemporary Immunology. Totowa, NJ: Humana Press.

Stewart IB, McKenzie DC (2002) The human spleen during physiological stress. Sports Medicine; 32: 6, 361-369.

Read the original here:
The lymphatic system 2: structure and function of the lymphoid organs - Nursing Times

NEW YORK, Oct. 30, 2020 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO) and certain of its officers. The class action, filed in United States District Court for the Southern District of New York, and docketed under 20-cv-09111, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Mesoblast securities between April 16, 2019 and October 1, 2020, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act").

If you are a shareholder who purchased Mesoblast securities during the class period, you have until December 7, 2020, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at http://www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [emailprotected]or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow. In February 2018, the Company announced that remestemcel-L met its primary endpoint in a Phase 3 trial to treat children with steroid refractory ("SR") acute graft versus host disease ("aGVHD").

In early 2020, Mesoblast completed its rolling submission of its Biologics License Application ("BLA") with the U.S. Food and Drug Administration ("FDA") to secure marketing authorization to commercialize remestemcel-L for children with steroid refractory aGVHD.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory aGVHD because of design differences between the four studies; (ii) as a result, the FDA was reasonably likely to require further clinical studies; (iii) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (iv) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 11, 2020, the FDA released briefing materials for its Oncologic Drugs Advisory Committee ("ODAC") meeting to be held on August 13, 2020. Therein, the FDA stated that Mesoblast provided post hoc analyses of other studies "to further establish the appropriateness of 45% as the null Day-28 ORR" for its primary endpoint. The briefing materials stated that, because of design differences between these historical studies and Mesoblast's submitted study, "it is unclear that these study results are relevant to the proposed indication."

On this news, the Company's American Depositary Share ("ADS") price fell $6.09 per share, or approximately 35%, to close at $11.33 per share on August 11, 2020, on unusually heavy trading volume.

On October 1, 2020, Mesoblast disclosed that it had received a Complete Response Letter ("CRL") from the FDA regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that the Company "conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD." The CRL also "identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product's biologic activity."

On this news, the Company's ADS price fell $6.56 per share, or over 35%, to close at $12.03 per share on October 2, 2020, on unusually heavy trading volume.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See http://www.pomerantzlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLP[emailprotected]888-476-6529 ext. 7980

SOURCE Pomerantz LLP

http://www.pomerantzlaw.com

See original here:
Pomerantz Law Firm Announces the Filing of a Class Action against and Mesoblast Limited Certain Officers - MESO - PRNewswire

The research report on Mesenchymal Stem Cells Market gives thorough insights regarding various key trends that shape the industry expansion with regards to regional perspective and competitive spectrum. Furthermore, the document mentions the challenges and potential restrains along with latent opportunities which may positively impact the market outlook in existing and untapped business spaces. Moreover, it presents the case studies, including the ones related to COVID-19 pandemic, to convey better understanding of the industry to all the interested parties.

The recent market trend of increasingly using Mesenchymal Stem Cells for understanding the development of a disease extensively fuel the growth of this market in the coming years. Another trend that will aid the growth of the global Mesenchymal Stem Cells market is the escalating demand for personalized medicine. Extensive investments are being made by various organizations, pharmaceutical companies, and governments for the research and development of drugs, and this is another trend that is benefiting the growth of the global Mesenchymal Stem Cells market. This is because Mesenchymal Stem Cells techniques enable researchers to compare Mesenchymal Stem Cells changes between disease samples and normal samples. Public health can thus be analyzed as the changes in Mesenchymal Stem Cells are influenced by internal biological system and environment directly.

Request a sample of this premium research: https://www.bigmarketresearch.com/request-sample/3921426?utm_source=Nilesh-EW

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include: Advanced Cell Technology Incorporated, Stem cell technologies Inc., Stemedica Cell Technologies, Inc., Cyagen Biosciences Inc., EMD Millipore Corporation, ScienCell Research Laboratories., Cytori Therapeutics Inc., Cell Applications, Inc., Axol Bioscience Ltd., Aastrom Biosciences, BrainStorm Cell Therapeutics., R&D Systems, Inc., Genlantis, Inc., Celprogen, Inc..

Mesenchymal Stem Cells Market Segmentation:

In market segmentation by types of Mesenchymal Stem Cells, the report covers-

Bone MarrowUmbilical Cord BloodPeripheral BloodLung TissueSynovial TissuesAmniotic FluidsAdipose Tissues

In market segmentation by applications of the Mesenchymal Stem Cells, the report covers the following uses-

InjuriesDrug DiscoveryCardiovascular InfractionOthers

Regional Analysis for Mesenchymal Stem Cells Market-:

1) North America- (United States, Canada)

2) Europe- (Germany, France, UK, Italy, Russia, Spain, Netherlands, Switzerland, Belgium)

3) Asia Pacific- (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam)

4) Middle East & Africa- (Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria)

5) Latin America- (Brazil, Mexico, Argentina, Colombia, Chile, Peru)

The report provides insights on the following pointers :

Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market

NOTE: Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on an exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement.

Request a discount on standard prices of this premium research: https://www.bigmarketresearch.com/request-for-discount/3921426?utm_source=Nilesh-EW

Table of Content

Chapter 1 Mesenchymal Stem Cells Introduction and Market Overview

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Global Mesenchymal Stem Cells Market, by Type

Chapter 5 Mesenchymal Stem Cells Market, by Application

Chapter 6 Global Mesenchymal Stem Cells Market Analysis by Regions

Chapter 7 North America Mesenchymal Stem Cells Market Analysis by Countries

Chapter 8 Europe Mesenchymal Stem Cells Market Analysis by Countries

Chapter 9 Asia Pacific Mesenchymal Stem Cells Market Analysis by Countries

Chapter 10 Middle East and Africa Mesenchymal Stem Cells Market Analysis by Countries

Chapter 11 South America Mesenchymal Stem Cells Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Global Mesenchymal Stem Cells Market Forecast

Chapter 15 New Project Feasibility Analysis

About Us:

Big Market Research has a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us:

Mr. Abhishek Paliwal

Big Market Research

5933 NE Win Sivers Drive, #205, Portland,

OR 97220 United States

Direct: +1-971-202-1575

Toll Free: +1-800-910-6452

E-mail: [emailprotected]

Go here to read the rest:
Mesenchymal Stem Cells Market Augmented Expansion to Be Registered by 2020-2025 - Eurowire

What is Adipose Tissue Derived Stem Cell Therapy?

Adipose tissue derived stem cells (ADSCs) are stem cells originated from adipocytes. ADSCs have characteristics similar to bone marrow mesenchymal stem cells. Thus Adipose-derived stem cells substitute for bone marrow as a source of stem cells. Different varieties of manual and automatic stem cell separation procedures are used to separate adipose stem cells (ASCs) from adipose tissue. Flow cytometry can be utilized to isolate ADSCs from other stem cells within a cell solution. Currently, adipose derived stem cells (ADSCs) are generally used in the generation of regenerative medicine due to its anti-inflammatory, anti-apoptotic, and immunomodulatory properties.

Download PDF Sample Report Here @ https://www.theinsightpartners.com/sample/TIPRE00014843/

The research provides answers to the following key questions:

A new market study report by The Insight Partners on the Adipose Tissue Derived Stem Cell Therapy Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets. Some of the key players in the study are AlloCure, Inc, Antria, Inc., Celgene Corporation, Cellleris SA, Corestem, Inc., Cytori Therapeutics, LLC, Intrexon, Inc., Mesoblast Ltd., Pluristem Therapeutics, Inc., Tissue Genesis, Inc. etc.

Market Insights:

The Adipose Tissue-derived Stem Cell Therapy Market is growing due to increasing use of regenerative medicine in disease treatment and increasing private and public funding for stem cell therapy. However, high cost associated with stem cell processing hampers growth of this market.

An Overview of the Impact of COVID-19 on this Market:

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Adipose Tissue Derived Stem Cell Therapy Market which would mention How the Covid-19 is Affecting the Adipose Tissue Derived Stem Cell Therapy Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Adipose Tissue Derived Stem Cell Therapy Players to fight Covid-19 Impact.

Adipose Tissue Derived Stem Cell Therapy Market: Regional analysis includes:

The Adipose Tissue Derived Stem Cell Therapy Market segments and Market Data Break Down are illuminated below:By Cell Type (Autologous Stem Cells, Allogeneic Stem Cells);

Product (Cell Line, Culture Media);

Disease (Cancer, Obesity, Wounds and Injuries, Musculoskeletal Diseases, Cardiovascular Diseases, Others);

End User (Hospitals and Trauma Centers, Cell banks and Tissue Banks, Research Laboratories and Academic Institutes, Others)

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Adipose Tissue Derived Stem Cell Therapy market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal with regard to different segments. The report predicts the influence of different industry aspects on the Adipose Tissue Derived Stem Cell Therapy market segments and regions.

This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Adipose Tissue Derived Stem Cell Therapy market.

Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure @ https://www.theinsightpartners.com/buy/TIPRE00014843/

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 10+ companies.

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

See the original post:
Adipose Tissue Derived Stem Cell Therapy Market to Set Phenomenal Growth in Key Regions by 2027 | AlloCure, Inc, Antria, Inc., Cellleris SA, Tissue...

Transparency Market Research (TMR) has published a new report titled, Cord Blood Banking Services Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, the global cord blood banking services market was valued at US$ 25.8 Mn in 2018 and is projected to expand at a CAGR of 10.9% from 2019 to 2027.

Overview

Request a PDF Sample https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1741

High Incidence of genetic disorders and rise in hematopoietic stem cell transplantation rates to Drive Market

Request for Analysis of COVID19 Impact on Cord Blood Banking Services Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1741

Private Cord Blood Bank Segment to Dominate Market

Purchase Cord Blood Banking Services Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=1741&ltype=S

North America to Dominate Global Market

Competitive Landscape

The global cord blood bank services market is fragmented in terms of number of players. Key players in the global market include Global Cord Blood Corporation, California Cryobank Stem Cell Services LLC, Inc., CBR Systems, Inc., Cordlife Group Limited, Cryo Cell International, Inc., Cryo-Save AG, Lifeforce Cryobanks, National Cord Blood Program, ViaCord, Inc., Virgin Health Bank among others.

More Trending Reports by Transparency Market Research

Incontinence Products Market: https://www.biospace.com/article/incontinence-products-market-rising-adoption-of-personal-hygiene-products-in-developing-economies-benefits-global-market/

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Continued here:
Cord Blood Banking Services Market is Anticipated to Expand at a CAGR of 10.9% from 2019 to 2027 - The Think Curiouser

The Global Hematopoietic Stem Cell Transplantation (HSCT) Market report offers key insights into the worldwide Hematopoietic Stem Cell Transplantation (HSCT) market. It presents a holistic overview of the market, with an in-depth summary of the markets leading players. The report is inclusive of indispensable information related to the leading competitors in this business sector and carefully analyzes the micro- and macro-economic market trends. The latest report specializes in studying primary and secondary market drivers, market share, the leading market segments, and comprehensive geographical analysis. Vital information about the key market players and their key business strategies, such as mergers & acquisitions, collaborations, technological innovation, and trending business policies, is one of the key components of the report.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3627

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

China Cord Blood Corp, Pluristem Therapeutics Inc., CBR Systems Inc CellGenix Technologie Transfer GmbH, Cryo-Save AG Kite Pharma Inc., Regen Biopharma Inc., ViaCord Inc., BiolineRx, Cynata Therapeutics, Cesca Therapeutics Inc, Lonza Group Ltd, TiGenix N.V., Bluebird Bio, Cellular Dynamics International, and Escape Therapeutics Inc., among others.

Furthermore, our market analysts have drawn focus to the significant impact of the COVID-19 pandemic on the global Hematopoietic Stem Cell Transplantation (HSCT) market and its key segments and sub-segments. The grave aftereffects of the pandemic on the global economy, and subsequently, on this particular business sphere, have been enumerated in this section of the report. The report considers the key market-influencing parameters, delivering a detailed future impact assessment. The Hematopoietic Stem Cell Transplantation (HSCT) market has been devastated by the pandemic, which has culminated in drastic changes to the market dynamics and demand trends.

In market segmentation by types of Hematopoietic Stem Cell Transplantation (HSCT), the report covers-

In market segmentation by applications of the Hematopoietic Stem Cell Transplantation (HSCT), the report covers the following uses-

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3627

Moreover, the research report thoroughly examines the size, share, and market volume of the Hematopoietic Stem Cell Transplantation (HSCT) industry in the historical years to forecast the same valuations over the forecast duration. It offers exhaustive SWOT analysis, Porters Five Forces analysis, feasibility analysis, and investment return analysis of the Hematopoietic Stem Cell Transplantation (HSCT) market, assessed using certain effective analytical tools. The report also provides strategic recommendations to market entrants to help them navigate around the entry-level barriers.

The global Hematopoietic Stem Cell Transplantation (HSCT) market is geographically categorized into:

The following timeline is considered for market estimation:

Historical Years: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Years: 2020-2027

Key Coverage of the Report:

To read more about the report, visit@ https://www.reportsanddata.com/report-detail/hematopoietic-stem-cell-transplantation-hsct-market

Thank you for reading our report. For further information or queries regarding the report, please get in touch with us. Our team will make sure your report is tailored according to your requirements.

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web: http://www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail: [emailprotected]

Link:
How Hematopoietic Stem Cell Transplantation (HSCT) Market Will Dominate In Coming Years? Report Covering Products, Financial Information,...

After tackling two major research challenges, the founders of Be Biopharma are ready to announce their official launch along with a $52 million funding round. They are intent upon usingthe bodys B cells to treat a range of diseases.

The Series A round was led by Atlas Venture and RA Capital Management. Joining in were Longwood, Alta Partners and Takeda Ventures.

We have an ambitious plan to be the company that knows how to make B cells and mirror them precisely and make them at scale, Aleks Radovic-Moreno, Be Biopharmas president and director, said in a phone interview.

B cells, which play a leading role in the bodys immune response, can be taken out, genetically programmed to help fight specific diseases and then put back in the body. The cells also can come from healthy donors.

The challenges involved being able to efficiently edit the cells and then make them in sufficient quantities, Radovic-Moreno said. Those are the two big problems we have overcome.

Founded this year, Be Biopharma is looking to hire people in research, engineering and manufacturing, as well as a full-time leadership team, said Radovic-Moreno, an entrepreneur in residence at Longwood Fund, a co-founder and investor in Be Biopharma. The startups CEO is David Steinberg, a general partner at Boston-based Longwood.

From there, the company hopes to begin developing therapeutics for use in people. Cancers and autoimmune diseases are potential targets, as are monogenic diseases like cystic fibrosis. B cells, for example, could replace the need for invasive bone marrow transplants, Radovic-Moreno said.

If we can do that, it would change the lives of so many people. So, were trying to move that as fast as humanly possible, said Radovic-Moreno, who declined to offer a specific timeline.

The path for B cells could be relatively quick, he said, based on the experience of T cells and stem cells, he said. B cell therapies, though, are expected to be safer and less toxic than those involving T cells.

Be Biopharma is drawing on research undertaken at the Seattle Childrens Research Institute by Dr. David Rawlings and Richard James. They are among the co-founders of the new company.

B cells play a key role in combatting diseases by catalyzing humoral immunity the arm of the immune system that manufactures large quantities of proteins to neutralize disease-causing pathogens and manipulate immune cell behavior, Rawlings, director of the Center for Immunity and Immunotherapies at the Seattle institute, said in a statement. Today, this powerful part of the immune system is only passively and/or indirectly addressed therapeutically. Our ambition is to advance the field by building a new class of engineered B cell medicines that will provide direct control over the power of humoral immunity and help transform the prognosis for patients who currently have limited treatment options.

Picture: Feodora Chiosea, Getty Images

Visit link:
Startup focused on B-cell therapies launched with $52M in Series A - MedCity News

Prophecy Market Insights has recently published the Stem Cell Therapy informational report which evaluates market size, growth rate, profit margin, raw material availability, impact strength, competition, technology, and environmental and legal factors.

The report covers all recent trends, opportunities, drivers, and restraints of the Stem Cell Therapy market coupled with their impact on demand over the forecast period. Additionally, the report provides a comprehensive view of the market by offering exhaustive value chain analysis. It provides in-depth information about value addition at each stage of the value chain.

Comprehensive information pertaining to fire alarm systems and its properties is provided in this section. This section also highlights the inclusions and exclusions, which help readers to understand the scope of the market report.

This segment includes factors that have emerged as key successful factors and strategies adopted by key market participants.

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3811

The Stem Cell Therapy market report provides a detailed analysis of market players according to its production footprint, market share, and growth rate. The report also covers SWOT analysis (strengths, weaknesses, opportunities, and threats) of the players. Besides, the Stem Cell Therapy market study depicts the recent launches, R&D projects, agreements, and business strategies of the market players including market segmentation and regional analysis of the market.

The Stem Cell Therapy market study covers both the top-down and bottom-up approaches that have been used to calculate and authenticate the market size and estimate the scenario of various sub-markets in the global market. The report estimation size of the market both in terms of volume (x units) and value (Mn/Bn USD).

Stem Cell Therapy Market by Top Manufacturers:

Scope of the Market Research Report:

The report takes into account the impact of the novel COVID-19 pandemic on the market and provides a clear assessment of the estimated market fluctuations throughout the forecast period.

Important Questions Answered in Stem Cell Therapy Market Report:

Segmentation Overview:

Global Stem Cell Therapy Market, By Treatment Type:

Global Stem Cell Therapy Market, By Cell Source:

Global Stem Cell Therapy Market, By Indication:

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/3811

Reasons to purchase the XYX market:

Provides recent collaborations, mergers, acquisitions, and partnerships along with regulatory framework across vast regions impacting the market trajectory

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Link:
Stem Cell Therapy Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - PRnews Leader

Tel Aviv, Israel , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Adding to a growing roster of partners, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced that it has entered into and commenced a collaborative development program with Sweden-based XNK Therapeutics, a pioneer in natural killer (NK) cell-based therapies.

This latest agreement demonstrates the continued progress and operational momentum we are continuing to generate, further validating our strategic vision and potential revenue opportunities, commented Dr. Shai Yarkoni, Chief Executive Officer. We join an already prestigious group of organizations that are currently collaborating with XNK Therapeutics, including the Karolinska Institute and the Royal Institute of Technology, and we are looking forward to fostering a long-term business and commercial collaboration. We remain focused on commercializing our functional cell selection technology so patients and markets can benefit from the proven safety profile and better outcomes of a broad range of cell and gene therapies.

Under the terms of the agreement, Cellect will help improve XNK Therapeutics technology platform, for targeting cancer across a wide range of indications. Cellect expects to expand the business arrangement based on the outcomes of the ongoing studies at XNK Therapeutics. Cellects functional cell selection technology has the potential to significantly improve the consistency and manufacturing efficiency in autologous as well as future allogeneic transplantation

XNK Therapeutics is expected to leverage Cellects simple, safe and inexpensive process as part of its efforts to create the next generation version of its innovative therapy platform. I am excited that we continue developing the next generation of XNK Therapeutics technology platform and looking forward to the collaboration with Cellect says Johan Liwing CEO of XNK Therapeutics.

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

Story continues

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Companys ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

ContactCellect Biotechnology Ltd.Eyal Leibovitz, Chief Financial Officerwww.cellect.co+972-9-974-1444

Or

EVC Group LLC Michael Polyviou(732) 933-2754mpolyviou@evcgroup.com

Read more:
Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional...

Careful, man, theres a beloved actor here.

Jeff Bridges revealed that he has lymphoma, which is the most common type of blood cancer. And this sobering news has spurred celebrities and fans to send their best wishes to the star best known for playing the Dude, the White Russiandrinking bowler and casual-wear icon from the Coen brothers 1998 cult classic, The Big Lebowski.

But the Dude abides, and Bridges suggested that his outlook looks just as promising.

As the Dude would say.. New S**T has come to light, tweeted Bridges, 70, on Monday. I have been diagnosed with Lymphoma. Although it is a serious disease, I feel fortunate that I have a great team of doctors and the prognosis is good.

Celebrities such as Cary Elwes, John Lithgow, Patricia Arquette and George Takei posted encouraging words and prayers to Bridges, who is the son of Lloyd and Dorothy Bridges, and has starred in more than 70 films including Starman, True Grit and The Last Picture Show. He won an Academy Award in 2010 for Crazy Heart, and was honored with the Cecil B. DeMille lifetime-achievement award during the 2019 Golden Globes.

And he is now one of the most high-profile cases of lymphoma, a cancer of the bodys infection-fighting lymphatic system that affects the blood and bone marrow. And more than 85,000 new cases of lymphoma are expected to be diagnosed in the U.S. this year, according to American Cancer Society data shared by the Leukemia & Lymphoma Society, with some 791,550 people currently living with lymphoma or in remission from the disease in the U.S.

Many different types of lymphoma exist, and Bridges did not share any more details about his diagnosis or treatment. But his disclosure is an opportunity to share more information about lymphoma, the risk factors and symptoms to be aware of, as well as treatment options.

What is lymphoma?

Lymphoma is a type of cancer that starts in cells that are part of the bodys immune system, specifically the lymphocytes, which are a type of white blood cell that fights germs. So these cancers can affect the blood and bone marrow, as well as the other tissues and organs that produce, store and carry white blood cells including the spleen.

Doctors still dont know what specifically causes lymphoma, but at some point a lymphocyte mutates and begins to reproduce rapidly. The mutated, abnormal cells live longer than the normal cells would, and in time, the diseased and ineffective lymphocytes outnumber the healthy cells, which causes the lymph nodes, liver and spleen to swell.

There are two main types of lymphoma, the CDC explains, including:

Hodgkin lymphoma (HL), which spreads in an orderly manner from one group of lymph nodes to another.

Non-Hodgkin lymphoma (NHL), which spreads through the lymphatic system in a non-orderly manner.

What are the symptoms?

Signs and symptoms of lymphoma may include:

These symptoms can be signs of other health conditions, of course, so its recommended that anyone experiencing them should see a doctor to determine the cause.

How is it treated?

There are many different types of lymphoma including 90 different types of non-Hodgkin lymphoma and treatment varies depending on the type and severity. Generally, lymphoma treatment involves chemotherapy, radiation therapy and immunotherapy medication. The Mayo Clinic, which is an international authority on lymphoma research, explains that the goal of treatment is to destroy as many cancer cells as possible to bring the disease into remission. A bone marrow or stem cell transplant may be performed in some cases to help rebuild healthy bone marrow after chemo and radiation has suppressed the diseased bone marrow.

Bridges didnt specify his own treatment, only saying that he is beginning treatment and will keep the public posted on his recovery.

Treatment can be very expensive, however, with almost 60% of patients covered by Medicare telling the Leukemia & Lymphoma Society in a 2019 study that they decided to delay or forego treatment, largely due to steep out-of-pocket costs. It noted that some traditional Medicare lymphoma patients getting anti-cancer therapy though infusions experienced out-of-pocket costs of more than $19,000 in their first year. And costs can extend two or three years beyond a blood cancer diagnosis.

Who is most at risk?

While children, teens and adults can all develop lymphoma, some types are more common in certain age groups. The CDC notes that rates of Hodgkin lymphoma are highest among teens and young adults (ages 15 to 39) as well as among older adults (ages 75 and older). But non-Hodgkin lymphoma becomes more common as people get older.

Men are also slightly more likely to develop lymphoma than women, the CDC adds, and white people are more likely than Black people to develop non-Hodgkin lymphoma.

Cases have also been more common in people who are immunocompromised, including those who take drugs to suppress their immune systems. And some infections such as HIV and the Epstein-Barr virus are also associated with an increased lymphoma risk.

And like many other cancers, family history has been linked with a higher risk of Hodgkin lymphoma.

What is the survival rate?

The good news is, Hodgkin lymphoma is now considered to be one of the most curable forms of cancer, according to the Leukemia & Lymphoma Society, with a five-year survival rate of 94.4% among patients younger than 45 at diagnosis. And the five-year relative survival rate for those with Hodgkin lymphoma more than doubled from 40% in whites in 1960 to 1963 (the only data available) to 88.5% for all races from 2009 to 2015.

And the five-year relative survival rate for people with non-Hodgkin lymphoma rose from 31% in whites from 1960 to 1963 (the only data available) to 74.7% for all races from 2009 to 2015.

Still, an estimated 20,910 Americans are expected to die from lymphoma this year, including 19,940 with non-Hodgkin lymphoma and 970 with Hodgkin lymphoma.

How does COVID-19 complicate things?

While the medical community is still learning about COVID-19, the general consensus is that people with cancer, who are in active cancer treatment or have previously been treated for cancer, may be at higher risk of severe illness and death if they get the coronavirus. So its important that these folks lower their risk of exposure to COVID-19 by avoiding large crowds and non-essential travel; working from home, if possible; staying at least six feet away from people outside their household; wearing a face mask when they cant socially distance; as well as washing their hands frequently, and not touching their eyes, nose or mouth.

Where can I find more information or support?

Visit the CDC and American Cancer Society pages on lymphoma.

The Mayo Clinic also outlines its lymphoma research and treatment strategies on its website.

The Leukemia & Lymphoma Society and the Lymphoma Research Foundation also provide valuable information and support.

Read more:
Jeff Bridges is one of the 85,000-plus lymphoma cases expected in the U.S. this year - MarketWatch

The report on Global Orthopedic Regenerative Medicine Market is a dependable point of reference heralding high accuracy business decisions on the basis of thorough research and observation by seasoned research professionals at CMI Research. The report on global Orthopedic Regenerative Medicine market evidently highlights the causal factors such as demand analysis, trend examination, and technological milestones besides manufacturing activities that have been systematically touched upon to instigate systematic growth projection.

This CMI Research report on global Orthopedic Regenerative Medicine market systematically studies and follows noteworthy progresses across growth trends, novel opportunities as well as drivers and restraints that impact growth prognosis.

Free Sample Report + All Related Graphs & Charts @:https://www.coherentmarketinsights.com/insight/request-sample/3566

Which market players and aspiring new entrants may witness seamless entry?

Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Predicting Scope: Global Orthopedic Regenerative Medicine Market, 2020-2027

Elaborate research proposes global Orthopedic Regenerative Medicine market is likely to experience an impressive growth through the forecast span, 2020-2027, ticking a robust CAGR of xx% USD. The Orthopedic Regenerative Medicine market is anticipated to demonstrate a whopping growth with impressive CAGR valuation. The Orthopedic Regenerative Medicine market is also likely to maintain the growth spurt showing signs of steady recovery.

For appropriate analysis of all the market relevant information as well emerging trends and historical developments in the Orthopedic Regenerative Medicine market, CMI Research has referred to various primary and secondary research practices and contributing factors.

Regional Overview: Global Orthopedic Regenerative Medicine Market

The report specifically sheds light upon note-worthy business discretion, popular trends investment probabilities aligning with budding opportunities as well as breakthrough developments in policies and monetary inclination echoing investor preferences in Orthopedic Regenerative Medicine space.

Competitive Landscape: Global Orthopedic Regenerative Medicine Market

Further in the report, readers are presented with minute details pertaining to significant company profiles, product development, on pricing, production and vital information on raw material and equipment developments also form crucial report contents in this CMI Research report.

Have Any Query? Ask Our Expert @: https://www.coherentmarketinsights.com/insight/request-customization/3566

Segmentation Based on Orthopedic Regenerative Medicine Market Types:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Global Orthopedic Regenerative Medicine Market Size & Share, By Regions and Countries/Sub-regions:

Asia Pacific: China, Japan, India, and Rest of Asia Pacific

Europe: Germany, the UK, France, and Rest of Europe

North America: the US, Mexico, and Canada

Latin America: Brazil and Rest of Latin America

Middle East & Africa: GCC Countries and Rest of Middle East & Africa

The regional analysis segment is a highly comprehensive part of the report on the global Orthopedic Regenerative Medicine market. This section offers information on the sales growth in these regions on a country-level Orthopedic Regenerative Medicine market.

The historical and forecast information provided in the report span between2020 and 2027. The report provides detailed volume analysis and region-wise market size analysis of the market.

Report Investment, a Priority: Explains CMI Research

This report also helps market participants to organize R&D activities aligning with exact market requirements

The report resonates critical findings on decisive factors such as downstream needs and requirement specifications as well as upstream product and service development

The report aids in reader comprehension of the market based on dual parameters of value and volume.

This CMI Research initiated research output on Orthopedic Regenerative Medicine market is a ready-to-refer handbook of noteworthy cues for easy adoption by market players and stakeholders

CMI Research skillfully underpins a vivid segment analysis of the global Orthopedic Regenerative Medicine market, rendering appropriate inputs about the revenue generation capabilities of each segment.

Buy this research report @: https://www.coherentmarketinsights.com/insight/buy-now/3566

Thanks for reading our report. If you have any further questions, please contact us. Our team will provide you with the report tailored to your needs.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702Email:[emailprotected]Web:https://www.coherentmarketinsights.com/

Here is the original post:
Covid-19 Impact On Orthopedic Regenerative Medicine Market 2020 Future Development, Manufacturers, Trends, Share, Size And Forecast to 2027 |...

This article was originally published here

N Engl J Med. 2020 Oct 27. doi: 10.1056/NEJMoa2026834. Online ahead of print.

ABSTRACT

BACKGROUND: Adult-onset inflammatory syndromes often manifest with overlapping clinical features. Variants in ubiquitin-related genes, previously implicated in autoinflammatory disease, may define new disorders.

METHODS: We analyzed peripheral-blood exome sequence data independent of clinical phenotype and inheritance pattern to identify deleterious mutations in ubiquitin-related genes. Sanger sequencing, immunoblotting, immunohistochemical testing, flow cytometry, and transcriptome and cytokine profiling were performed. CRISPR-Cas9-edited zebrafish were used as an in vivo model to assess gene function.

RESULTS: We identified 25 men with somatic mutations affecting methionine-41 (p.Met41) in UBA1, the major E1 enzyme that initiates ubiquitylation. (The gene UBA1 lies on the X chromosome.) In such patients, an often fatal, treatment-refractory inflammatory syndrome develops in late adulthood, with fevers, cytopenias, characteristic vacuoles in myeloid and erythroid precursor cells, dysplastic bone marrow, neutrophilic cutaneous and pulmonary inflammation, chondritis, and vasculitis. Most of these 25 patients met clinical criteria for an inflammatory syndrome (relapsing polychondritis, Sweets syndrome, polyarteritis nodosa, or giant-cell arteritis) or a hematologic condition (myelodysplastic syndrome or multiple myeloma) or both. Mutations were found in more than half the hematopoietic stem cells, including peripheral-blood myeloid cells but not lymphocytes or fibroblasts. Mutations affecting p.Met41 resulted in loss of the canonical cytoplasmic isoform of UBA1 and in expression of a novel, catalytically impaired isoform initiated at p.Met67. Mutant peripheral-blood cells showed decreased ubiquitylation and activated innate immune pathways. Knockout of the cytoplasmic UBA1 isoform homologue in zebrafish caused systemic inflammation.

CONCLUSIONS: Using a genotype-driven approach, we identified a disorder that connects seemingly unrelated adult-onset inflammatory syndromes. We named this disorder the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. (Funded by the NIH Intramural Research Programs and the EU Horizon 2020 Research and Innovation Program.).

PMID:33108101 | DOI:10.1056/NEJMoa2026834

See original here:
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease - DocWire News

CRISPR And CRISPR-Associated (Cas) Genes Market Scope of the Report:

Factors and CRISPR And CRISPR-Associated (Cas) Genes Market execution are analyzed using quantitative and qualitative approaches to give a consistent picture of current and future trends in the boom. The study also allows for a detailed market analysis focused primarily on geographic locations. The Global CRISPR And CRISPR-Associated (Cas) Genes Market Report offers statistical graphs, estimates, and collateral that explain the state of specific trade within the local and global scenarios.

The worldwide market for CRISPR And CRISPR-Associated (Cas) Genes is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2025, from xx million US$ in 2018, according to a new study.

This report focuses on the CRISPR And CRISPR-Associated (Cas) Genes in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2649968&source=atm

Sales and Pricing AnalysesReaders are provided with deeper sales analysis and pricing analysis for the global CRISPR And CRISPR-Associated (Cas) Genes market. As part of sales analysis, the report offers accurate statistics and figures for sales and revenue by region, by each type segment for the period 2015-2026.In the pricing analysis section of the report, readers are provided with validated statistics and figures for the price by players and price by region for the period 2015-2020 and price by each type segment for the period 2015-2020.Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global CRISPR And CRISPR-Associated (Cas) Genes market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of sales for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global CRISPR And CRISPR-Associated (Cas) Genes market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global CRISPR And CRISPR-Associated (Cas) Genes market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global CRISPR And CRISPR-Associated (Cas) Genes market.The following manufacturers are covered in this report:Caribou BiosciencesAddgeneCRISPR THERAPEUTICSMerck KGaAMirus Bio LLCEditas MedicineTakara Bio USAThermo Fisher ScientificHorizon Discovery GroupIntellia TherapeuticsGE Healthcare DharmaconCRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by TypeGenome EditingGenetic engineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line EngineeringCRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by ApplicationBiotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2649968&source=atm

Reasons to Purchase this CRISPR And CRISPR-Associated (Cas) Genes Market Report:

* Analyzing the outlook of the market with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

* 1-year analyst support, along with the data support in excel format.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2649968&licType=S&source=atm

The CRISPR And CRISPR-Associated (Cas) Genes Market report has 150 tables and figures browse the report description and TOC:

Table of Contents

1 Study Coverage

1.1 CRISPR And CRISPR-Associated (Cas) Genes Product

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type

1.5 Market by Application

1.5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application

2 Executive Summary

2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size

2.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue 2014-2025

2.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Production 2014-2025

2.2 CRISPR And CRISPR-Associated (Cas) Genes Growth Rate (CAGR) 2019-2025

2.3 Analysis of Competitive Landscape

2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

2.3.2 Key CRISPR And CRISPR-Associated (Cas) Genes Manufacturers

2.3.2.1 CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Base Distribution, Headquarters

2.3.2.2 Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Product Offered

2.3.2.3 Date of Manufacturers Enter into CRISPR And CRISPR-Associated (Cas) Genes Market

2.4 Key Trends for CRISPR And CRISPR-Associated (Cas) Genes Markets & Products

3 Market Size by Manufacturers

3.1 CRISPR And CRISPR-Associated (Cas) Genes Production by Manufacturers

3.1.1 CRISPR And CRISPR-Associated (Cas) Genes Production by Manufacturers

3.1.2 CRISPR And CRISPR-Associated (Cas) Genes Production Market Share by Manufacturers

3.2 CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers

3.2.1 CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers (2019-2025)

3.2.2 CRISPR And CRISPR-Associated (Cas) Genes Revenue Share by Manufacturers (2019-2025)

3.3 CRISPR And CRISPR-Associated (Cas) Genes Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

More Information.

For More Information Kindly Contact:

marketresearchhub

Mr. Rohit Bhisey,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Read the original here:
CRISPR And CRISPR-Associated (Cas) Genes Market: Drivers, Restraints, Opportunities, and Threats (20192025) - Eurowire

As we know, COVID-19 is causing large scale loss of life and severe human suffering. With the pandemic spreading across the globe, researchers are racing against the clock to develop diagnostic tools, vaccines and treatments. Recently, WHO has launched a Solidarity clinical trial to assess relative effectiveness of four potential drugs against COVID-19. Further, there are close to 40 clinical trials of vaccines are ongoing, however, as per experts, it may take more than a year to develop a vaccine.

In order to enhance COVID-19 drug discovery and develop rapid testing kits, various academic institutes, non-profit institutes, scientific pioneers and biopharmaceutical companies have also been leveraging benefits of CRISPR technology.

For more Insights Click under

CRISPR Can be a Solution to Address the COVID-19 Pandemic

The CRISPR / Cas9 system has revolutionized the field of genetic engineering. It enables researchers to alter the genomes of a range of organisms with relative ease. Currently, it has emerged as a promising tool that is used extensively for editing genomes and for the development of novel treatment options. CRISPR is popularly known as search engine for biology, as it has emerged as a location finder, rather than site specific cleavage tool. The figure below highlights the key potential areas and benefits of CRISPR in order to fight against novel coronavirus.

Rapid and Economical Diagnostic Tests

Presently, COVID-19 testing capacity is limited by a number of factors, such as requirements for complex procedures, need for laboratory instrumentation, and dependence on limited supplies. Therefore, there is an urgent need for rapid detection kits. CRISPR has been explored by scientists for diagnosis of infectious diseases. The underlying mechanism involves binding of guide RNA with a protein of Cas family which cuts the target and shreds the nearby RNA or DNA. When CRISPR hits a target, the reporter molecule releases a fluorescent signal. This is further analysed by paper tests dipped into a patient sample, such as blood, urine, or saliva, which further shows up as a line on the testing strip. Researchers have been utilizing CRISPR-based tools and technologies to detect RNA of virus in patient samples. Sherlock Biosciences has already made history, as it received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19. The kit is designed for use in laboratories and can provide results within an hour. The company claims that more than 1 million tests can be performed within a week.

Enhancing Drug Discovery

CRISPR technology aids in the study of interaction of virus with human cells. This enables the generation of appropriate cell models for faster discovery of new potential treatment options, or identification of an existing drug combination that may provide a treatment solution. For instance, researchers are exploring molecular mechanisms of the novel virus by utilizing CRISPR technology, which can ultimately assist in identifying potential drug combinations.

CRISPR-based COVID-19 Therapy

Researchers at Stanford University have been working on the development of a gene targeting anti-viral agent against COVID-19, using PAC-MAN technology. The technology has been modified to be used against the deadly virus. It consists of a virus-killing enzyme, such as Cas13 and a guide RNA, which commands Cas13 to destroy specific nucleotide sequences in the coronaviruss genome. Based on several studies, it has been revealed that PAC-MAN has the ability to neutralize the coronavirus and stop it from replicating inside cells. Based on information available, work is currently ongoing, and researchers are finding a solution to deliver this technology to lung cells. Multiple delivery methods are currently under evaluation.

A lot of companies are currently active in providing CRISPR-based genome engineering services. To get a detailed information on the key players, recent developments, and the likely market evolution.

For more Insights Click under

CRISPR Can be a Solution to Address the COVID-19 Pandemic

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

Visit link:
CRISPR Can be a Solution to Address the COVID-19 Pandemic | Roots Analysis - The Think Curiouser

Genome editing may be one of the solutions to address climate change. A September 2020 report by the Information Technology & Innovation Foundation (ITIF),Gene Editing for the Climate: Biological Solutions for Curbing Greenhouse Emissions, emphasizes that gene-editing technology could be used to develop clean energy and climate solutions that policymakers have to date under-emphasized.

CRISPR and the newer gene-editing applications are also being used to address food issues by reducing apple or potato browning and tomato softening to extend the shelf life of produce. In addition, disease-resistant fruits are under development, such as the Panama disease resistant Cavendish bananas that are being field tested by Tropic Biosciences.

Furthermore, many companies are focusing on extending the nutritional value of food by adding more protein to soy and other staple crops, and making oils, including soybean and canola, healthierAnother firm of note, Pairwise Plants, is working to develop new and delicious types of leafy greens, berries, and cherries, along with other efforts in staple crops.

The role of technology and its impact on agriculture is unprecedented. According to [Yeild10s OIiver] Peoples, it is important to start by looking at fundamentals in a scientific way and first ask whether a change makes sense; if it has a meaningful impact and is sustainable.

Read the original post

Visit link:
Picking up where GMOs left off: CRISPR leads the way to 'greener' food production in the 21st century - Genetic Literacy Project